Tuesday report

Tuesday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC,

  • Beckers Payer Issues tells us,
    • “House Minority Leader Hakeem Jeffries, D-NY, has endorsed lowering the Medicare eligibility age and expanding the program’s benefits, along with guaranteeing health coverage for all children. 
    • “Speaking at a Nov. 17 press conference on Capitol Hill, Mr. Jeffries said Democrats would first move next year to reverse the Medicaid cuts enacted under HR 1 and reinstate the enhanced ACA premium subsidies that expired at the end of 2025, priorities the party had previously outlined as part of its first-100-days plan. 
    • “A return to the status quo is not acceptable,” Mr. Jeffries told reporters. “We should lower the age of Medicare eligibility. We should expand coverage to include vision, hearing and dental. And we should cover all the kids in the United States of America. Those are bold actions, meaningful actions, important actions that can be taken on our march toward universal health coverage.”
    • “Mr. Jeffries, who is widely expected to become the next speaker of the House on Jan. 3, didn’t say what age he would support lowering the Medicare eligibility threshold to, but the endorsement goes further than the healthcare agenda House Democrats had laid out ahead of the midterms.”
  • Per a Senate Judiciary Committee news release,
    • “Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) today chaired a hearing to examine the high cost of prescription drugs and proposed legislative solutions. Last year, the Judiciary Committee advanced six Grassley-backed, bipartisan bills to lower prescription drug prices through competition transparency and to address anticompetitive tactics in the pharmaceutical supply chain. One of those bills, the Affordable Prescriptions for Patients Act, passed the Senate unanimously in July. The remaining bills have not received a vote on the Senate floor.
    • “Today’s witnesses urged Congress to pass bipartisan legislation and echoed Grassley’s calls for the Federal Trade Commission (FTC) to complete its 6(b) study of pharmacy benefit managers (PBMs).” 
  • Per STAT News,
    • “The Trump administration is pulling its nominee to lead the Food and Drug Administration, Heidi Overton, according to a White House official and a source close to Overton.
    • “The decision follows concerns that Overton, a preventive care doctor who previously served in the Trump White House, lacked sufficient support from Republicans on the Senate’s health panel, which had been expected to vote on her nomination Wednesday.”
  • The Wall Street Journal reports,
    • “President Trump’s nominee to lead the Government Accountability Office, Eric Ueland, is facing concerns from several Senate Republicans.
    • “Republican Senators Thom Tillis, Susan Collins and John Curtis have raised concerns about moving a White House budget official into the GAO role.
    • “Critics and Democrats argue that Eric Ueland is too partisan and that the nomination process bypassed the required bipartisan consultation.”
  • Today, two weeks after election day, the Centers for Medicare and Medicaid Services “released the 2027 Medicare Part A and Part B programs premiums, deductibles, and coinsurance, and the 2027 Medicare Part D income-related monthly adjustment amounts.” * * *
    • “The Medicare Part A inpatient hospital deductible that beneficiaries pay if admitted to the hospital will be $1,776 in 2027, an increase of $40 from $1,736 in 2026.” * * *
    • “The standard monthly premium for Medicare Part B enrollees will be $209.40 for 2027, an increase of $6.50 from $202.90 in 2026. The annual deductible for all Medicare Part B beneficiaries will be $292 in 2027, an increase of $9 from the annual deductible of $283 in 2026.” 
       
  • CMS adds,
    • Helping doctors, hospitals, and other healthcare providers work together is paying off for Medicare and taxpayers, with the largest savings in the Medicare Shared Savings Program’s history. The program yielded more than $2.5 billion in net savings to Medicare in 2025, marking its ninth consecutive year of saving taxpayer dollars. These results underscore the promise of accountable care — bringing healthcare providers together around patients’ needs while rewarding quality and reducing unnecessary spending.
    • In 2025, every participating Accountable Care Organization (ACO) met or exceeded Medicare’s quality reporting requirements, underscoring continued focus on providing better care and improved health outcomes.
  • Per an Department of Health and Human Services news release,
    • “The U.S. Department of Health and Human Services (HHS), through the Administration for Community Living (ACL), today announced a cooperative agreement totaling more than $3 million to USAging for the National Resource Center on Nutrition and Aging (NRCNA). The three-year award will strengthen Senior Nutrition Programs, funded by the Older Americans Act, by providing national leadership, training, technical assistance, data infrastructure, and resources that help communities improve nutrition services for older adults.”
  • Healthcare Dive adds its perspective on yesterday’s final rule amending the HIPAA Privacy Rule.
    • “HHS Office for Civil Rights Director Paula Stannard said she’s “convinced” the rule will enable health data sharing and better care coordination.”

From the U.S. Office of Personnel Management front,

  • Beckers Payer Issues picks up on the GLP-1 drug coverage changes in the FEHB and PSHB Programs for 2027.
  • Legis1 tells us,
    • “Phased retirement, which allows eligible federal employees to work half-time while drawing part of their pension, remains limited in use, according to a new Congressional Research Service (CRS) report. ​
    • “Data from the Office of Personnel Management (OPM) counted 1,533 initial phased retirements and 1,375 composite retirements from Nov. 6, 2014, through Oct. 13, 2026. That left 158 employees in phased retirement status as of Oct. 13, 2026.
    • Six agencies have each have had more than 100 participants [cumulatively], with the National Aeronautics and Space Administration reporting the most, at 222.
    • Participation depends on agency approval. CRS notes that phased retirement is not an entitlement and that not all federal agencies offer the program.”

From the U.S. Food and Drug Administration front,

  • Cardiovascular Business reports,
    • “One lot of generic propranolol hydrochloride extended-release capsules has been recalled due to a potential risk metal contamination. New Jersey-based Breckenridge Pharmaceutical issued a statement about the recall, highlighting the risks of consuming these capsules.
    • “Propranolol hydrochloride is a beta-blocker often prescribed to treat hypertension or arrhythmias. It has also been known to reduce migraine symptoms due to its effect on blood vessels in the brain. Propranolol hydrochloride has been sold under various brand names, but this specific recall is for one lot of a generic version of the drug.
    • “Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach or intestine,” the company explained. “The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market.”
    • “Breckenridge Pharmaceutical emphasized that no adverse events have been linked to this issue. However, due to the risk, the company is urging patients to “immediately stop” taking the capsules and reach out to a healthcare provider for “medical advice and replacement instructions.” Patients have also been asked to return any unused medications to where they originally obtained them.” 
  • Per FDA news releases,
    • “The U.S. Food and Drug Administration today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA’s regulatory drug and biologic approval decisions are leveraged by health authorities around the world. The GRDP marks a major step forward in the FDA’s global leadership and may accelerate patient access to innovative therapies throughout the world.
    • “The GRDP enables the FDA to more efficiently share minimally redacted approval packages, including the FDA’s detailed scientific and regulatory assessments, directly with companies who can then share them with regulatory authorities outside of the United States, empowering those authorities to rely on the FDA’s rigorous, science-based review decisions rather than conducting duplicative and time-consuming product evaluations of their own, while maintaining sovereignty over their regulatory decision.”
  • and
    • “The U.S. Food and Drug Administration today approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer. Lembaz is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, also known as infantile-onset NPC.
    • “For families living with Niemann-Pick disease type C, today’s approval marks an important milestone,” said Acting FDA Commissioner Kyle Diamantas, J.D. “For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community.”
  • Fierce Pharma relates,
    • “On a hot streak, GSK has won a third high-profile FDA approval in recent weeks, this time for the second lung cancer drug from the British pharma’s $10.6 billion acquisition of Nuvalent earlier this year.
    • “Marking just the second commercial lung cancer drug in GSK’s history, the FDA has clearedNelkarmi, or neladalkib, for previously treated ALK-positive non-small cell lung cancer (NSCLC).
    • “Compared with the company’s first lung cancer approval, gained in July for legacy Nuvalent’s Jideytro in ROS1-positive NSCLC, Nelkarmi targets a larger patient population and carries greater commercial potential. When Royalty Pharma acquired a royalty interest in the two drugs at the end of 2025, it cited analysts’ consensus sales projections of $3.5 billion for Nelkarmi by 2035, versus $1.9 billion for Jideytro.”
  • MedTech Dive tells us,
    • “Medtronic said Tuesday the Food and Drug Administration has cleared the Hugo robotic system for use in general surgery procedures.
    • “The clearance covers all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia and small bowel resection. Two lower abdominal procedures, inguinal hernia and appendectomy, were also cleared. 
    • “Medtronic said the combined procedures account for about 3.5 million annual surgeries in the U.S., or more than half of the soft tissue procedures performed each year.”

From the public health and medical / Rx research front,

  • The American Hospital Association News reports,
    • “The United States has lost its elimination status for measles, the Pan American Health Organization announced Nov. 17. The group, which is a regional arm of the World Health Organization, determined that the virus has sustained transmission for more than a year. The U.S. earned its elimination status designation in 2000. As of Nov. 12, there have been 5,412 confirmed cases of measles in the U.S. this year, according to the Centers for Disease Control and Prevention.” 
  • Beckers Clinical Leadership adds,
    • “During U.S. measles outbreaks from Jan. 1, 2025, to Sept. 28, 2026, 112 pregnant women were infected and 13 babies were born with congenital measles, according to a preliminary CDC analysis published Nov. 16 in NEJM Evidence. 
    • “It is the first national picture of measles complications in pregnancy in decades, assembled as the virus surged to its highest levels since the disease was declared eliminated in the U.S.
    • “Almost all of the infected women — 98% — had not received the measles-mumps-rubella vaccine before pregnancy or had an unknown vaccination status. Because MMR is a live vaccine that is not given during pregnancy, protection in this group depends on vaccination before pregnancy and high community coverage, the authors wrote.
    • “Twenty-six of the 112 women, or 23%, were hospitalized for reasons unrelated to labor. Eleven developed pneumonia; two had respiratory failure and one was admitted to the ICU, according to the CDC scientists’ findings as reported by The Washington Post.” * * *
    • “The report urges clinicians to prepare emergency departments, labor-and-delivery units and NICUs for cases many have never seen, to give unvaccinated exposed pregnant patients immune globulin within six days of exposure, and to administer immune globulin to exposed newborns at birth.”
  • On the bright side, Beckers Clinical Leadership relates,
    • “The U.S. five-year survival rate for lung cancer has increased from 18.1% in 2018 to 31%, according to the American Lung Association’s 2026 “State of Lung Cancer” report published Nov. 16.
    • “Despite nationwide improvement, lung cancer is still the leading cause of cancer deaths in the U.S., and survival rates were considerably lower across states and among certain racial and ethnic groups.
    • “We must continue to drive progress on lung cancer screening, comprehensive biomarker testing, clinical trials and effective treatments to help people live longer, fuller lives after a lung cancer diagnosis,” Harold Wimmer, president and CEO of the American Lung Association, said in a Nov. 16 news release from the American Lung Association.” 
  • Per a CDC news release,
    • “New CDC surveillance data show that the rate of new diabetes cases among U.S. adults increased from 2020 through 2025 after decreasing for more than a decade. 
    • “CDC is continuing research to identify factors contributing to this trend. Potential contributing factors include a change in screening practices that may result in more detection of previously undiagnosed diabetes and lifestyle changes during the COVID-19 pandemic that could increase risk for type 2 diabetes. Additionally, as the population ages, this demographic shift could contribute to an upward trend in the number of people with newly diagnosed diabetes. Adults 45 and older face higher risk for type 2 diabetes.
    • “It’s important that people know their risk for diabetes, take steps to prevent or delay type 2 diabetes, and manage diabetes if they already have it. 
    • “Resources include:
  • The American Medical Association lets us know,
    • “Pancreatic cancer will become the second-leading cause of cancer-related death in the U.S. by 2030. About 10% to 15% of those pancreatic cancers originate from cysts. While it sounds ominous, “it’s something that we can actually intervene upon before it has the opportunity to turn into cancer,” according to Christopher Chapman, MD, a gastroenterologist with Rush University System for Health in Chicago. 
    • Pancreatic cysts are extremely common but often cause anxiety for patients. Standard treatment usually involves surveillance imaging such as MRIs or CT scans, endoscopic procedures, or more invasive surgery.
    • “Rush is one of the few hospitals in the country and the only facility in Illinois that has been pioneering a chemoablation method for treating pancreatic cysts that pose a cancer risk. Under this procedure, physicians use endoscopic ultrasound to place a fine needle directly into the cyst to inject targeted chemotherapy.  
    • “Initially the words ‘chemo’ make patients feel unsettled, but because only a small volume is placed directly into the cyst, there is no additional risk for the significant side effects that people typically think of.  Due to its safety and effectiveness, we felt that patients in the Chicagoland area and in the Midwest in general should have the opportunity to access this novel approach close to home,” said Dr. Chapman, who joined Rush gastroenterologist Neal Mehta, MD for an interview with the AMA about the procedure.” 
  • Per MedPage Today,
    • “Vietnam-era military veterans exposed to the weedkiller Agent Orange had a higher risk of developing Parkinson’s disease and other neurodegenerative synucleinopathies, a study of more than 4 million Veterans Affairs (VA) health records showed.
    • “Agent Orange exposure was associated with a 57% greater risk of developing a synuclein-based neurodegenerative disorder (HR 1.57, 95% CI 150-1.63), said Gregory Scott, MD, PhD, of the Oregon Health & Science University (OHSU) and the VA Portland Health Care System, and colleagues.
    • “This included increased risks for Parkinson’s disease (HR 1.44, 95% CI 1.37-1.52), rapid eye movement (REM) sleep behavior disorder (HR 1.78, 95% CI 1.68-1.89), and dementia with Lewy bodies (HR 1.66, 95% CI 1.32-2.09), the researchers reported in JAMA Neurology.”
  • and tells us
    • “Deaths attributable to cancers related to high body mass index (BMI) have more than doubled over the past three decades, according to U.S. data.
    • “Using estimates from the Global Burden of Disease 2023 study, cancer deaths linked to a BMI of 25 or higher increased 104.2%, from 23,236 in 1990 to 47,450 in 2023, reported Digantkumar Patel, MD, of the Springfield Clinic in Illinois.
    • “During this period, the age-standardized death rate increased by 8.1%, from 7.28 to 7.87 per 100,000 people. That uptick indicates that the rise in obesity-related cancer deaths “cannot be explained by population growth and aging alone,” Patel said at the ObesityWeek annual meeting.
    • “We all know about the association between obesity and cancer, but we have less information about how much the burden of these cancers has changed over time,” he noted, suggesting that pinpointing the fastest-growing malignancies can help target screening and prevention.
    • “Our findings reinforce the importance of obesity prevention and treatment as a part of cancer prevention,” Patel added.”
  • Here’s a link to a JAMA special report titled “Toward a Healthier Future Through Obesity Prevention and Care”
  • Health Day informs us,
    • “Three patterns of brain activity can be found among children with ADHD, anxiety or a mix of the disorders
    • “MRI brain scans revealed two distinct types of brain connection problems among kids with the disorders
    • “The two types of brain dysfunction combine in different ways to create the three activity patterns.”
  • and
    • An hourlong memory exam outperforms commonly used 10-minute tests in checking cognitive ability
    • The exam detected mild cognitive impairment in 40% of seniors who were judged normal by the shorter test
    • The longer exam also found dementia in nearly 9% of those who had scored normal.
  • FEHBlog observation: In May 2025, the FEHBlog took a four hour long cognitive ability test and came out with flying colors.
  • The Washington Post points out,
    • “A first of its kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday, marking another positive result in a breakthrough year for cancer vaccines.
    • “Patients given the vaccine, galinpepimut-S (GPS), had a 41 percent reduction in risk of death compared to those given other treatments for leukemia, according to Sellas, which presented initial data from a trial of 126 patients.
    • “GPS was tested on patients who achieved a second or later complete remission for leukemia, meaning patients who were successfully treated for the disease at least twice. Acute myeloid leukemia, which affects around 20,000 people a year in the United States, is usually treated with chemotherapy, but remnants of the cancer often remain and recurrence is common.”
  • Per Fierce Pharma,
    • “AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a global phase 3 trial.
    • “In patients with early Alzheimer’s disease, AriBio’s mirodenafil candidate, AR1001, delivered better clinical outcomes than placebo did—but only in a subgroup of patients who were not on any background therapies such as an acetylcholinesterase inhibitor or memantine, according to results from the Polaris-AD trial.
    • “In the overall population, including those receiving other therapies at baseline, the trial missed statistical significance on change in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at week 52. The data were shared at the Clinical Trials on Alzheimer Disease conference in Boston. 
    • “The trial is technically positive, as it’s designed with dual primary populations, each with its separate statistical significance bar. AriBio said it plans to discuss the results with the FDA.”

From the U.S. healthcare business and artificial intelligence front,

  • Kaufmann Hall released its September 2026 National Hospital Flash Report today.
    • “Performance remains tenuous as the external environment pressures hospitals’ financial health. Year-to-date median operating margin dipped to 1.1% in September, when adjusted for allocations. Ongoing challenges, including payer mix, rising bad debt, and charity care, along “with expense growth above the rate of inflation, continue to strain hospitals’ financial health.
    • Bifurcation of hospital performance is becoming more pronounced. The margin gap between higher- and lower-performing hospitals has widened to 19 percentage points, with a historically large portion of hospitals operating at negative or very thin margins. Even slight revenue reductions threaten organizations, which face increasingly difficult decisions on future operations, care delivery, and expense control.
    • “Deliberate, proactive steps can help hospitals build financial resilience. The ongoing migration to outpatient, along with other reimbursement pressures, reinforce the importance of organizations taking a holistic view of operations, including coverage, payer mix, utilization, revenue, cost, service portfolios, and community needs. Strategic decisions made now will help shape how organizations are positioned for the future.
    • “To view more insights on trends affecting hospitals and steps you can consider taking to address them, download the latest issue of the National Hospital Flash Report.”
  • Beckers Payer Issues relates,
    • “Pittsburgh-based Highmark reported $26.5 billion in revenue through the third quarter of 2026.
    • “According to a Nov. 17 news release, Pittsburgh-based Highmark Health had $741 million in operating income and $1.9 billion in net income for that period. Net income includes non-cash gains of $911 million stemming from two completed affiliations: Blue Cross and Blue Shield of Kansas City and Beaver, Pa.-based Heritage Valley Health System.
    • “Top-line revenue growth was $1.9 billion, which included $1.4 billion for Blue KC and $105 million for Heritage Valley. During the first nine months of 2025, revenue was $24.6 billion with $204 million in operating and $69 million in net losses.” 
  • Fierce Healthcare tells us,
    • “Humana is continuing its push to reform prior authorization with the launch of a national provider gold card program.
    • “The program will go into effect on Dec. 1, the company announced Tuesday. It will focus initially on MRI, CT and MRA imaging as well as physical and occupational therapy. Through the program, eligible providers will no longer need to secure a prior authorization approval and can instead use a streamlined process.
    • “Humana estimates that about 50,000 providers will qualify for the program. Eligible providers must be able to demonstrate a proven track record of high-quality care and patient outcomes.”
  • Healthcare Dive informs us,
    • “Name: Dr. Matthew Callstrom
    • “Previous title: Medical director for the strategy department and the artificial intelligence program, Mayo Clinic
    • “New title: Incoming president and chief executive officer, Mayo Clinic
    • “Callstrom will take the reins of the Minnesota-based health system on Jan. 1. 
    • “Since 2002, Callstrom has held various leadership positions at Mayo Clinic, spanning clinical practice, research, strategy and AI. He currently leads the health system’s strategy department and generative AI program, helping shape organizational strategy and efforts to integrate AI into medicine, Mayo said in a press release Friday.
    • “The health system is an early and prominent adopter of AI, using the technology to identify new drugs, detect diseases sooner and support clinical decision-making.
    • “Callstrom will succeed Dr. Gianrico Farrugia, who was CEO for eight years before announcing that he would step down in May.”
  • Beckers Hospital Review points out,
    • “UnitedHealth Group’s pharmacy benefit manager, Optum Rx, has launched three digital tools for members, building on its model designed for more transparency announced earlier in 2026.
    • “According to a Nov. 17 post, Shop MyScript alerts members of savings opportunities soon after a prescription is written. The tool is integrated into the prescribing workflow, allowing members to review options before a prescription is sent to the pharmacy. If a member does not engage, prescriptions are routed to the member’s typical pharmacy.
    • “Eighty-three percent of eligible members have interacted with Shop MyScript since its launch. Optum Rx said average member savings are more than $28 per claim, or script.
    • “Another tool is Optum Price Wise, powered by Fuze Health. When customers are not using health benefits to purchase medications and need to pay with cash, Price Wise shows a full cost breakdown, encompassing the drug price and fees. 
    • “The third tool is Optum Assistant, a conversational AI experience that answers questions about medications, benefits and the pharmacy experience. Optum Assistant intends to efficiently surface information, carry out common tasks and connect to live support if necessary. Optum Rx reported that roughly 80% of these conversations assisted people without requiring further help.”
  • Per STAT News,
    • “For years, researchers and investors have been searching for a treatment that’s as effective in treating sickle cell disease as gene therapy — but without the many drawbacks. 
    • “Biotech entrepreneur Romesh Subramanian thinks he might have one. On Tuesday, he announced the founding of new startup Marrow Therapeutics to pursue it, with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed, and others.”
    • “We expect it to be as good as [gene therapy] in patients,” Subramanian said, “but to be proven for sure.”
  • Here’s a link to Fierce Healthcare’s HLTH conference tracker.

Monday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC.

  • The American Hospital Association News reports,
    • “In comments provided Nov. 16 to majority and minority leaders of the House and Senate, the AHA requested Congress to act on key priorities for hospitals and health systems before the end of 2026. The AHA urged Congress to extend healthcare programs set to expire at the end of the year, including the Medicare-dependent Hospital and the Low-volume Adjustment programs, the work geographic practice cost index floor, the clinical laboratory fee schedule, the National Health Service Corps, the Conrad State 30 Program and the Cybersecurity Information Sharing Act of 2015. The AHA also recommended Congress provide protections for the 340B Drug Pricing Program, stabilize and maintain access to long-term care hospitals, reject site-neutral payment expansions and improve insurer accountability.”
  • and
    • “The Department of Labor released an enforcement alert Nov. 13 to employers and health plan fiduciaries to ensure that plan participants and beneficiaries are receiving accurate provider directories for in-network coverage. The department said the alert stemmed from a secret shopper survey conducted by the Employee Benefits Security Administration, which contacted 27,000 providers across 27 networks and found that 36% of directories had incorrect information. The alert includes best practices and questions to ask providers on how they maintain and update their directories.” 
  • Per a Department of Health and Human Services news release,
    • “The U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) today announced a Final Rule, HIPAA Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens. This final rule strengthens individuals’ rights to access their own protected health information (PHI), including electronic PHI through personal health apps; improves information sharing for care coordination and case management; and reduces regulatory and administrative burdens on covered entities.
    • * * * “The final rule includes the following modifications to the Privacy Rule:
    • “Strengthens the Individual Right of Access
      • “Reduces the amount of time that covered entities have to respond to individuals’ requests for copies of their PHI.
      • “Establishes that the individual right of access includes the right of an individual to obtain a copy of their electronic PHI through a personal health app when the covered entity has the capability to produce the PHI in that form and format.
      • “Amends the permissible fees for responding to right of access requests, including by establishing when copies of PHI must be provided to the individual for free, and requires advance notice of fees.
      • “Implements the right of access to direct a covered entity to transmit an electronic copy of PHI in an electronic health record to a person designated by the individual.
      • “Reduces the burden of identity verification on individuals exercising their access rights.
    • “Facilitates Care Coordination
      • “Clarifies that health plans may use and disclose PHI for care coordination and case management for individuals and expressly permits covered entities to disclose PHI to social services agencies, community-based organizations, and similar third parties for care coordination and case management for individuals.
    • “Reduces Regulatory Burdens
      • “Eliminates requirement to make a good faith effort to obtain from individuals written acknowledgment of receipt of a Notice of Privacy Practices.
      • “Permits disclosures to Telecommunications Relay Services (TRS) communications assistants for persons who are deaf, hard of hearing, or deaf-blind, or who have a speech disability, and excludes TRS providers from the definition of business associate.
      • “Permits certain disclosures of PHI of United States Public Health Service and National Oceanic and Atmospheric Administration Commissioned Corps personnel to command authorities for mission readiness, expanding on a previous permission that applied only to the Armed Forces.
    • “This final rule is effective 60 days after publication. The Final Rule may be viewed here: https://www.federalregister.gov/public-inspection/2026-23429/hipaa-privacy-rule-changes-to-support-coordinated-care-and-individual-engagement-and-reduce
    • “View The Final Rule Fact Sheet here: https://www.hhs.gov/hipaa/for-professionals/privacy/changes-support-coordinated-care-individual-engagement-reduce-regulatory-burdens-final-rule.html.”
  • Federal New Network relates,
    • “The White House is pushing for a top Office of Management and Budget official to be the next leader of the Government Accountability Office, setting up a lame duck battle over the future of the Congressional watchdog.
    • “President Donald Trump on Monday formally nominated OMB Deputy Director Eric Ueland to serve as the next comptroller general. Ueland also served in the first Trump administration. A former Senate staffer, he has been instrumental in the second Trump administration’s efforts to reshape the federal bureaucracy.
    • “Ueland’s nomination comes after Senate Homeland Security and Governmental Affairs Committee Chairman Rand Paul (R-Ky.) cleared a path for the White House to name a comptroller general nominee without getting bipartisan input from Congress.
    • “Paul has scheduled a Thursday hearing for Ueland, along with nine other nominees.”
  • Per a National Institutes of Health news release,
    • “National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D., today announced the selection of John H. Powers III, M.D., as director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Dr. Powers currently serves as NIAID Acting Director and Principal Deputy Director and as an infectious diseases attending physician for the institute in the NIH Clinical Center. NIAID conducts and supports basic and applied research to better understand, treat and ultimately prevent infectious, immunologic and allergic diseases.  
    • “Dr. Powers is a physician-scientist who has spent more than three decades caring for patients, teaching and mentoring the next generation of investigators, and playing an integral role in research that improves lives. He has been a trusted and valued colleague within NIAID for several decades, and will bring a focus on rigor, transparency, and research outcomes to leading the institute into the future.,” said Dr. Bhattacharya. “I am thankful for his commitment to serve and glad to permanently welcome him to the NIH leadership team.” 

From the U.S. Office of Personnel Management front,

  • Federal News Network offers an interview with Shelly Giuliano about how to shop for a health plan during the ongoing Open Season.
  • Kevin Moss, writing in Federal News Network, points out that
    • “One of the most significant changes in Federal Employees Health Benefits next year is centered around GLP-1 prescription drugs. Their popularity is growing fast: Roughly one in eight U.S. adults now takes a GLP-1 for weight loss or to help manage a chronic condition. Spending has climbed even faster. For the two carriers that represent 69% of FEHB members, an Office of Personnel Management inspector general report found GLP-1 spending rose more than 500%, from $392 million in 2019 to $2.6 billion in 2024.
    • “In response to these rising costs, OPM has introduced a new prior-authorization requirement for everyone in any FEHB plan who receives a GLP-1 prescribed for weight loss. Most carriers have also raised the cost-share to 50%.
    • “I’ll share all the details about these changes plus ways federal employees and annuitants can save money on GLP-1s next year.”

From the U.S. Food and Drug Administration front,

  • STAT News reports,
    • “The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever.
    • “The approval of Wilserdly, also known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology. 
    • “The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. The evERA trial showed that the drug, an oral treatment known as a selective estrogen receptor degrader, or SERD, extended the time period before patients’ tumors progressed.”
  • and
    • “The Food and Drug Administration is proposing a new classification for a product that’s existed in a legal gray area for years, a win for proponents of dietary supplements, including members of the MAHA movement. 
    • “The proposed rule would classify N-acetyl-L-cysteine, known as NAC and already widely sold over the counter, as the agency’s first “Dietary Ingredient Not Excluded from the Dietary Supplement Definition” — in essence, not not a supplement. 
    • “The need for the legal backbending stems from the fact that the FDA previously approved NAC as a drug, and FDA regulations prohibit the agency from including approved drugs in the dietary supplement category. In 1963, the agency approved NAC to break up mucus in certain lung conditions, and in 1985 to treat acetaminophen overdose.” 
  • Beckers Hospital Review relates,
    • The FDA has rejected Summit Therapeutics’ application for ivonescimab for certain patients with advanced lung cancer after the treatment did not show a statistically significant improvement in overall survival.
    • “Summit said the FDA cited the finding in rejecting the drug, according to a Nov. 15 news release. The application sought approval of ivonescimab with platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer who had previously received a third-generation EGFR-targeted therapy. The FDA issued a complete response letter, saying substantial evidence of effectiveness was not established without a statistically significant overall survival improvement. The agency’s decision date was Nov. 14.”
  • Per Fierce Pharma,
    • As Roche’s Gazyva comes under pressure in blood cancer, the anti-CD20 antibody keeps expanding its reach in autoimmune diseases.
    • In its third U.S. indication for an immune-mediated condition, Gazyva has become the first FDA-approved treatment for primary membranous nephropathy (pMN), a rare disease where the immune system mistakenly attacks the tiny filtering units in the kidneys.
    • The drug is specifically approved to reduce proteinuria, or the abnormal presence of protein in the urine, which is a key indicator of kidney damage.
  • Radiology Business tells us,
    • “The U.S. Food and Drug Administration has cleared a new imaging artificial intelligence software for brain aneurysm detection, the product’s developers announced Friday. 
    • “Uptunity was designed to support radiologists and other physicians in spotting signs of this clinical concern on CT angiography, along with aiding in follow-up assessments. The software was developed by contrast-agent manufacturer Bracco in collaboration with Avicenna.AI. 
    • “The two note that 1 in every 50 U.S. adults suffer an unruptured brain aneurysm, a condition that is often asymptomatic and difficult to detected on images. 
    • “A small incidental aneurysm on a head CTA can easily be overlooked when the work list keeps growing,” Cosimo DePinto, executive VP of marketing and commercial operations for Bracco Americas, said in a statement Nov. 13. “Uptunity Aneurysm works inside the reading environment radiologists already know and helps find the aneurysm hiding in the CT scan. The clinical decision stays where it belongs: with the radiologist.”
  • MedTech Dive informs us,
    • “MiniMed received Food and Drug Administration clearance for its first tubeless insulin pump, the company said on Monday. 
    • “The device, called MiniMed Fit, can be worn for up to seven days and has an insulin capacity of 300 units. It’s cleared for people with Type 1 and Type 2 diabetes ages seven and older.
    • “MiniMed will compete with market leader Insulet and Tandem Diabetes Care, which just debuted its first tubeless pump, giving people with diabetes more options.”

From the fraud, waste, and abuse front,

  • Per a Centers for Medicare and Medicaid Service news release,
    • “The Centers for Medicare & Medicaid Services (CMS), a division of the U.S. Department of Health and Human Services (HHS), today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the agency’s ability to prevent, identify, and address fraud, waste, and abuse across Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and the Health Insurance Marketplace.
    • “The Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule is a standalone, discretionary rule that proposes changes to strengthen program integrity by enhancing provider screening and enrollment safeguards, requiring prompt self-reporting and return of identified fee-for-service overpayments, improving managed-care program-integrity reporting to better oversee potential fraud and improper payments, increasing provider-ownership transparency and data reporting for oversight agencies, and intensifying scrutiny of deductions from Medicaid payments.” * * *
    • “CRUSH would advance the Trump Administration’s commitment to making fraud prevention a core responsibility across federal healthcare programs. Building on stakeholder input and record program integrity results, the proposal would strengthen CMS’ ability to intervene earlier, hold providers and plans accountable, and protect coverage and care for millions of Americans.
    • “CMS encourages public comment on the proposed rule. Comments are due Jan. 19, 2027.
    • “The proposed rule is available in the Federal Register at: https://public-inspection.federalregister.gov/2026-23461.pdf [PDF]
    • “View the proposed rule fact sheet at: https://www.cms.gov/newsroom/fact-sheets/comprehensive-regulations-uncover-suspicious-healthcare-crush-proposed-rule-cms-6098-p“

From the public health and medical / Rx research front,

  • Beckers Clinical Leadership reports,
    • “When the Pan American Health Organization confirmed Nov. 14 the U.S. lost the measles elimination status it held since 2000, Michael Osterholm, PhD, was not surprised.
    • “Many of us believe that we had lost our elimination status many months ago,” said Dr. Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota in Minneapolis. “So to me, this was much more about a technical definition than it was about a reality. The reality was we’ve been in big trouble with measles in this country for months.”
    • “As of Nov. 12, the CDC had recorded 5,412 measles cases this year across 46 states and the District of Columbia, with 11% of patients hospitalized. Dr. Osterholm told Becker’s [in this article] what the shift means for hospitals and what it would take to reverse it.”
  • The American Medical Association tells us what doctors ants patients to know about joint replacements.
    • “Joint replacement is no longer just for older adults. Here’s what every patient needs to know about surgery, implant longevity, recovery and revision.”
  • The New York Times explains why “Why a Little Extra Weight May Benefit Older People.
    • “Even in the age of obesity drugs, researchers say many don’t need to shed pounds.”
  • FEHBlog observation – A dietician once told me that while people should avoid an obese BMI, an overweight BMI is acceptable for seniors because if a senior contracts an acute illness, he or she is likely to lose weight which is hard to put back on.
  • The Wall Street Journal informs us,
    • “Novo Nordisk showed its drug Wegovy helped children age 6 to 11 with obesity lose weight, though they grew more slowly on average than peers.
    • “In a study of adolescents, Eli Lilly’s drug Zepbound reduced body-mass index by an average of 18.5%.
    • “Both drugs improved other health markers like blood sugar and some measures of cholesterol.” 
  • Health Day lets us know,
    • “An erratic sleep schedule can contribute to mood disorders
    • “People with irregular sleep and wake times had higher levels of anxiety, depression and loneliness
    • “As little as a half hour additional variation in sleep can impact mood.”
  • Healio adds,
    • “A study projected a 10-year jump in median age for people with HIV by 2040.
    • “This shifting demographic will present new challenges for healthcare.”
  • STAT News relates,
    • “A cancer immunotherapy from CG Oncology delivered into the bladders of patients reduced the risk of tumor recurrence by 68% compared to current medical practice — positive study results announced Monday that may change the way physicians treat certain patients with bladder cancer.
    • “The CG Oncology treatment, called cretostimogene, is made from a type of common cold virus engineered to target cells that express a specific mutation found in bladder tumors. Physicians use a catheter to infuse “creto” directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, then breaks open the cells, killing them.” * * *
    • “On Monday, the company said it was delaying its submission to the Food and Drug Administration until March 2027 in order to incorporate new clinical data that could lead to an approval encompassing a larger proportion of these high-risk patients. 
    • “Previously, CG Oncology had said its initial FDA submission for high-risk bladder cancer would be completed by the end of the year. 
    • “We’re just shifting by three months, and we’re gonna own the March date that we feel confident in,” said CG Oncology CEO Arthur Kuan. 
    • “Discussions with the FDA about how to best seek approval of creto to treat intermediate-risk bladder cancer remain ongoing, Kuan added.” 
  • Beckers Hospital Review notes,
    • “Active U.S. drug shortages stood at 225 at the end of the third quarter, similar to the past three quarters, according to the American Society of Health-System Pharmacists. The 87 new shortages reported through September nearly equal the 89 reported for all of 2025, and chemotherapy shortages in particular have outlasted drugmakers’ resupply estimates. The FDA’s database continues to reflect new discontinuations weekly.
    • “The article identifies] six recent shortage and discontinuation listings, according to the FDA database.”

From the U.S. healthcare business and artificial intelligence front,

  • MedCity News reports,
    • “Many health technologies develop without input from the end users they’re meant to serve: clinicians and frontline medical workers. Now, The Permanente Medical Group (TPMG), the country’s largest physician-led medical group and part of Kaiser Permanente, is putting those clinicians in the driver’s seat of healthcare innovation. 
    • “TPMG, part of Kaiser Permanente, announced Monday the launch of Permanentech, a new physician-led healthcare innovation company designed to turn frontline clinical insights into technology products, partnerships, and independent businesses.
    • “The announcement, made during the annual HLTH conference in Las Vegas, offers a different approach to healthcare innovation: rather than developing technology in isolation and then trying to persuade clinicians to adopt it, Permanentech intends to put physicians at the center of the process.” 
  • Healthcare Dive adds,
    • “Healthcare remains the AI industry’s biggest vertical, with health AI investments ballooning to $3.7 billion — more than double the past year, according to a new Menlo Partners report.
    • “Provider organizations are looking to deploy AI in new areas, with the most popular ones being front-office operations and clinical copilots, the report shows.
    • “Even though established health IT companies continue to dominate the ambient scribing space, providers are increasingly turning to startups for AI-driven clinical and administrative tools.”
  • and
    • “GLP-1s for weight loss, diabetes and other conditions can save employers and other payers money — if they’re priced at $350 per month or less, according to a new analysis by CVS Health.
    • “The white paper, released Sunday during the HLTH conference in Las Vegas, found that GLP-1s are associated with better health outcomes, fewer hospitalizations and lower medical spending. But at their current sky-high prices, pharmacy spending on GLP-1s swamps any medical savings for plan sponsors, CVS found. Per the Employee Benefit Research Institute, employers typically pay between $617 and $766 a month for GLP-1s.
    • “The goal of the white paper is to pressure drugmakers like Eli Lilly and Novo Nordisk to lower the cost of the popular medications, according to Dr. Amy Compton-Phillips, CVS’ chief medical officer.”
  • Beckers Hospital Review lets us know,
    • “Cleveland Clinic recorded operating income of $326.6 million (6.5% operating margin) during the third quarter of 2026, up from operating income of $206.2 million (4.5% margin) during the same period last year, according to its Nov. 16 financial report.”
  • and
    • “Minnesota Attorney General Keith Ellison’s office entered into a 10-year oversight agreement with Sacramento, Calif.-based Sutter Health and Minneapolis-based Allina Health, completing its review of Allina’s plan to join Sutter.
    • “Mr. Ellison said Nov. 16 that the deal meets the public interest standard under Minnesota’s healthcare transaction law. His office does not approve such deals, but it can seek court relief if it later finds the transaction is no longer in the public interest. The review included two public meetings and more than 675 written comments.”
  • The Wall Street Journal relates,
    • “Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion.
    • “The purchase price includes an undisclosed upfront payment, along with clinical and regulatory milestone payments.
    • “Calytrix Bio is developing therapies aimed at myeloproliferative neoplasms, which are a group of rare blood cancers.”
  • and
    • “Johnson & Johnson JNJ has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for an initial $2.2 billion, and has struck a deal with asset manager Blackstone to fund development of Ollin’s lead asset.
    • “J&J on Monday said the Ollin deal, which includes more than $1.12 billion in potential regulatory and commercial milestone payments, adds OLN324, an investigational bispecific antibody for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.”
  • Here’s a link to Fierce Healthcare’s HLTH Conference tracker.

Weekend update

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC,

  • Roll Call offers more details on this week’s Capitol Hill activities here.
  • The Wall Street Journal reports,
    • “The Pan American Health Organization has revoked the measles-elimination status of the U.S., according to people familiar with the matter.
    • “The U.S. CDC has reported more than 5,400 measles cases in 2026, a level not seen since before the disease was eliminated in 2000.
    • “To regain elimination status, the U.S. must halt the continuous spread of the highly infectious disease for at least 12 months.”
  • The Office of Management and Budget’s Office for Information and Regulatory Affairs has cleared for publication in the Federal Register that Department of Health and Human Services’s Office for Civil Rights long awaited “HIPAA Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens” final rule. The final rule should appear in the Federal Register this week.

From the U.S. Office of Personnel Management front

  • The Federal Employee Benefits Open Season heads into its second week tomorrow.
  • Serving Those Who Serve offers guidance on how to get all of the tax benefits from a health savings account.

From the judicial front,

  • In Human Rights Campaign’s case against OPM over its ban on gender affirming care in the FEHB and PSHB Programs, the federal district judge Hon. Amit P. Mehta issued the following briefing order last Thursday.”
    • “MINUTE ORDER setting the schedule for further proceedings in this matter: (1) Defendants shall file a consolidated Opposition to Plaintiffs’ Motions for Preliminary Injunction and Provisional Class Certification and Cross-Motion to Dismiss on or before November 24, 2026; (2) Plaintiffs shall file a consolidated Reply in Support of their Motions for Preliminary Injunction and Provisional Class Certification and Opposition to Defendants’ Cross-Motion to Dismiss on or before December 7, 2026; and (3) Defendants shall file their Reply in Support of their Cross-Motion to Dismiss on or before December 14, 2026. Signed by Judge Amit P. Mehta on 11/12/2026. (lcapm2) (Entered: 11/12/2026).”

From the public health and medical / Rx research front,

  • Health Exec reports,
    • “Note to patients suffering low-back pain without having signs or symptoms of severe injury or illness: You’ll do well for yourself—and for U.S. healthcare—to get an X-ray at an urgent-care clinic rather than going to a hospital emergency room for more advanced imaging. 
    • “That’s the conclusion of researchers who found only 24 of almost 3,000 urgent-care lumbar X-rays—less than 1%—preceded a pricey CT or MRI scan at an ER within 30 days. 
    • “The low follow-up rate adds to evidence suggesting most low-back pain subsides without need for additional imaging, much less professional intervention or other downstream episodes of care. 
    • “Given the population-level pattern, the findings suggest, a quick X-ray can help confidently rule out serious harm when none appears to be present. 
    • “This should come as good news to watchers of medical spending, as advanced imaging for low-back pain has often been referred to as the “poster child” for healthcare overutilization.” 
  • Healio relates,
    • “The cost of GLP-1 receptor agonists is one of the strongest predictors for continued medication use among adults with diabetes or obesity, according to a speaker at ObesityWeek.
    • “In an analysis of data from adults in the U.S. who participated in the Understanding America Study (UAS), researchers examined GLP-1 efficacy and usage in a real-world setting. Weight loss totals in the study were similar to what were observed in clinical trials, but the study found that 33.4% of participants stopped treatment. Additionally, discontinuation was more likely among those who were paying more than $51 per month in out-of-pocket spending.
    • “Cost, not just side effects, shapes who gets these drugs and who stays on them,” Alison Sexton Ward, PhD, senior scholar and research scientist at the University of Southern California Schaeffer Institute for Public Policy and Government Service, told Healio. “Need drives interest: People with higher BMI or [worse] diabetes are much more interested in GLP-1s than people with lower BMI. But income and insurance determine who actually starts. And once people start, paying more than $50 a month out of pocket raises the risk of stopping as much as, or more than, having vomiting as a side effect. These drugs can produce substantial weight loss that builds over time, but only for people who can afford to stay on them.”
  • and
    • “Adults with obesity who used either semaglutide or tirzepatide at baseline were able to maintain weight loss at 2 years across four separate treatment regimens, according to data presented at ObesityWeek.
    • “In an analysis of data from adults with obesity who were using either injectable once-weekly semaglutide (Ozempic/Wegovy, Novo Nordisk) or tirzepatide (Mounjaro/Zepbound, Eli Lilly) at baseline, researchers compared changes in body weight and other cardiometabolic parameters among different management strategies. While adults who underwent bariatric surgery achieved the largest weight loss at 2 years, those who switched between semaglutide and tirzepatide had a greater weight loss than those who remained on their baseline medication. All four groups who continued some form of obesity therapy had greater weight loss at 2 years than the group that stopped treatment.
    • “Our study highlights the importance of continued obesity management,” Hamlet Gasoyan, PhD, investigator at the center for value-based care research at Cleveland Clinic and assistant professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, told Healio. “These results could support patient-clinician discussions about alternative therapy options in patients who consider switching or stopping injectable semaglutide or tirzepatide.”
  • Health Day informs us,
    • “More than 1 in 5 U.S. adults report very high stress, and most now see it as unavoidable
    • “Chronic stress keeps the body in fight-or-flight mode, raising risks of heart disease, diabetes, depression and dementia
    • “Time outdoors, healthy eating, rest, less news and staying connected can help keep stress from turning chronic.
  • and
    • “Multiple trips to the ER. Treatment for a severe allergic reaction. And years without the right diagnosis.
    • “Two new studies reveal how a condition called eosinophilic esophagitis, or EoE, is being mistaken for severe food allergies.
    • “Researchers say diagnoses have increased sevenfold since 2009.
    • “EoE is a chronic condition often triggered by foods like dairy and wheat.
    • “Unlike a typical food allergy, it causes a buildup of white blood cells in the esophagus — the tube connecting your mouth to your stomach.
    • “This causes swelling and irritation. Over time, it can make swallowing difficult and cause food to get stuck. * * *
    • “Experts urged people with recurring swallowing problems but negative tests for food allergies to speak with their doctor.
    • “Early diagnosis and treatment can help prevent lasting damage to the esophagus.”

From the U.S. healthcare business front,

  • AlphaSense lists the 50 largest healthcare companies by market cap.
    • “Eli Lilly is the largest company in the healthcare and pharma space, with a market cap of $1.29 trillion.
    • “Eli Lilly is followed by Johnson & Johnson ($655.46 billion), AbbVie ($511.22 billion), Merck & Co ($363.24 billion), and UnitedHealth Group ($355.78 billion). 
    • “The largest market cap companies mostly fall into the pharma and health insurance sub-sectors.
    • “Biotech, medical devices, and medtech are some of the fastest growing sub-sectors.”
  • The American Medical Association points out,
    • “9 health systems finding success in physician recruitment, retention
      • “From mentorship to well-being, health systems across the U.S. are finding creative ways to improve work environments to keep doctors engaged.”
  • Per Business Wire,
    • “Unified Women’s Healthcare (Unified), one of the nation’s largest women’s healthcare organizations, is leading a new initiative to explore how routine OB/GYN care can play a greater role in identifying and addressing cardiovascular disease risk among women. Early support from the American Heart Association Go Red for Women Venture FundTM for a feasibility study by Unified’s Lucina Analytics subsidiary laid the groundwork for the initiative. Building on that foundation, Unified is leveraging Lucina’s AI-driven intelligence and embedded care management capabilities to help OB/GYN teams identify patients at elevated cardiovascular risk and connect them with care tailored to their risk level.
    • “Cardiovascular disease remains the leading cause of death among women in the United States, yet opportunities to identify risk factors and intervene early are often missed. For many women, their OB/GYN is their most consistent point of contact within the healthcare system, creating an important opportunity to integrate cardiovascular prevention into care they already receive.
    • “The Unified initiative seeks to bridge this gap by developing a scalable approach to cardiovascular risk assessment within women’s healthcare settings, with the long-term goal of helping clinicians identify women at elevated risk earlier and connect them with appropriate preventive services and specialty care.”

Friday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC,

  • Modern Healthcare reports,
    • “House Democratic leader Hakeem Jeffries said he would push to expand Medicare and lower the program’s eligibility age as he detailed the party’s emerging legislative agenda at a Denver conference.
    • “Jeffries outlined a Democratic House agenda centered on reversing Medicaid cuts, restoring ACA subsidies, and lowering Medicare’s eligibility age.
    • “Senate passage of Medicare changes remains uncertain, as Republican filibuster support and a potential Trump veto pose significant obstacles.”
  • Beckers Payer Issues notes,
    • “U.S. Reps. Adrian Smith, R-Neb., and Debbie Dingell, D-Mich., introduced a bill that would create a five-year pilot for skilled nursing facility services to be administered at home, according to a Nov. 12 news release.
    • “The Bringing Rehabilitation, Integrated Delivery and Greater Extended Care at Home Act, or BRIDGE Care at Home Act, would establish a Medicare “SNF-at-Home” program Jan. 1. Under the program, eligible entities could deliver SNF services at a patient’s home, as long as that patient already qualifies for SNF coverage under Medicare Part A. The release said Medicare currently covers qualifying skilled nursing care in a facility but lacks a comparable payment model for that care at home.
    • “With the program, the standard of care must be the same for at-home and inpatient SNF treatment. The services would be paid for under current Medicare SNF payment rules, out of the Hospital Insurance Trust Fund.”
  • Federal News Network adds,
    • “House Democrats are looking to quash the Trump administration’s proposal for a governmentwide non-disclosure agreement for federal employees.
    • “Reps. Greg Landsman (D-Ohio) and Raja Krishnamoorthi (D-Ill.) on Thursday introduced the No Disrupting Accountability (NDA) Act. The legislation, if enacted, would prohibit federal funding from being used to “develop, finalize, implement, administer or enforce” the administration’s blanket NDA proposal.
    • “Government employees should never be silenced from exposing waste, fraud, abuse and corruption — and federal funds should never be used to allow it,” Landsman said. “Our bill will make sure taxpayer dollars protect the public interest.”
  • The American Hospital Association News relates,
    • “The Centers for Medicare & Medicaid Services Nov. 13 announced it will delay enforcement of its Medicaid community engagement requirements that are set for Jan. 1. CMS is providing states an optional hold harmless transition period through June 30, 2027, for continued preparation efforts. CMS said that states implementing the hold harmless period will assess whether individuals meet the requirements or are excluded from it, but they will not deny applications or disenroll eligible individuals solely for failure to meet the requirements. The community engagement requirements call for certain adults to complete 80 hours per month of “qualifying activities,” such as employment, education, community service or participation in a work program, or meet equivalent income thresholds.”
  • Healthcare Dive tells us,
    • “Federal agencies plan to hold a series of events where payers, providers and health IT developers can test electronic workflows for prior authorization as the federal deadline for some insurers to automate the process looms.
    • “Hosted by the Office of the National Coordinator for Health IT and the CMS, the events will allow the organizations to test their software and identify gaps before a Jan. 1 deadline that requires health plans to support electronic prior authorizations.
    • “The testing events will last 10 to 12 weeks, and interested organizations must register with the CMS by Nov. 20.”

From the U.S. Office of Personnel Management front,

  • Federal News Network offers interviews with a bevy of experts about the ongoing Federal Employee Benefits Open Season.
  • FedSmith reports,
    • “The annual contribution limit for the Thrift Savings Plan (TSP) is increasing to $25,500 in 2027, according to an announcement from the Internal Revenue Service (IRS). This is a 4.1% increase over the 2026 limit of $24,500.” * * *
    • “The catch-up contribution limit for employees aged 50 and older is rising to $8,500 in 2027, up from $8,000 in 2026, according to IRS Notice 2026-66. This means TSP participants who are 50 or older can contribute a total of $34,000 next year.
    • “Under the SECURE 2.0 Act of 2022 (SECURE 2.0), employees aged 60, 61, 62 and 63 have a higher catch-up contribution limit. For 2027, that limit is increasing to $11,750, up from $11,250 in 2026. Participants in this age group can contribute up to $37,250 to the TSP in 2027.
    • “Higher earners should keep in mind that catch-up contributions must be made to the Roth TSP if their prior-year wages exceed an IRS threshold. For 2027 catch-up contributions, that threshold is $155,000 in 2026 wages, up from $150,000 in 2025 wages for this year.”
  • Govexec relates,

From the U.S. Food and Drug Administration front,

  • MedTech Dive reports,
    • “The Food and Drug Administration posted two early alerts on Tuesday for medical devices that are being removed from the market.
    • “Teleflex subsidiary Arrow International recalled certain spring wire guide components used as part of a system to place catheters in blood vessels. Arrow told customers on Nov. 5 to quarantine and cease use and distribution for affected products, according to the FDA alert.
    • “On the same day, the agency posted an alert for Intersurgical, which sent customers a letter on Nov. 3 recommending they immediately stop using certain breathing tubes and systems due to a manufacturing issue.”
  • JAMA relates,
    • “The US Food and Drug Administration (FDA) approved bepirovirsen, marketed as Hibsago, in combination with existing antiviral therapy for adults without cirrhosis who have chronic hepatitis B virus (HBV) infection.
    • “The first-in-class drug is intended for patients who have received antiviral therapy for at least 6 months, have suppressed HBV viral DNA levels, and have hepatitis B surface antigen levels of 3000 IU/mL or less. The antisense oligonucleotide works by targeting viral genetic material and interfering with replication.
    • “In 2 clinical trials, 24% of patients who received bepirovirsen met criteria to stop their background antiviral therapy, compared with none in the placebo group. About 6 months after stopping all hepatitis B treatment, nearly 20% of treated patients maintained viral control. Still, the drug carries a boxed warning for serious liver reactions and thrombocytopenia.”

No Surprises Act News,

  • Healthcare Dive reports,
    • “Senator Bill Cassidy, R-La., the outgoing chair of the Senate Health, Education, Labor and Pensions Committee, plans to soon release legislation reforming the No Surprises Act, according to a top aide.” * * *
    • “Cassidy, one of the authors of the NSA, has been working on “comprehensive legislation” to restore the law’s key goals, including encouraging providers to go in-network with insurers and lowering healthcare costs broadly, Romney Gripado, a health policy advisor to Cassidy, said during a Thursday event hosted by the Georgetown University Center on Health Insurance Reforms in Washington, D.C.
    • “Our proposal, which will be released soon, focuses on strengthening program integrity, improving oversight of [arbiters], restoring accountability, increasing transparency around the entire dispute resolution process, and ensuring that the dispute resolution process is fair and predictable for those involved,” Gripado said. “We’re also focused on protecting employers from unnecessary costs, ensuring that providers are compensated in a timely fashion, and addressing the incentives that might be driving increased utilization of arbitration.”

From the public health and medical / Rx research front,

  • The Centers for Disease Control and Prevention announced today,
    • “COVID-19, flu, and RSV are key indicators of overall respiratory illness activity
    • “The amount of acute respiratory illness causing people to seek health care is low but increasing.
      • “RSV activity is low in most areas of the country.
      • “COVID-19 activity is low nationally.
      • “Seasonal flu activity continues to increase in many parts of the country.
      • “Rhinovirus/Enterovirus (RV/EV) and respiratory adenovirus (HAdV) are elevated nationally. Respiratory adenovirus is increasing in some regions of the country.”
  • The American Hospital Association News reports,
    • “Pennsylvania has recorded its seventh measles-associated death this year as a statewide outbreak of the virus continues, according to an update Nov. 13 by the state’s Department of Health. There are now 1,542 confirmed cases in the outbreak, with 305 hospitalizations. Nationwide, there are now 5,412 confirmed measles cases in 2026, according to data released Nov. 13 by the Centers for Disease Control and Prevention. The vaccination status of 96% cases is unvaccinated or unknown.”
  • The Univerity of Minnesota’s CIDRAP adds,
    • “With 174 new infections, Wisconsin reported the most measles cases of any US state over the past week.
    • “In Pennsylvania, the country’s other major measles hot spot, officials confirmed 61 new infections over the past week. Its 2026 case count of 1,542 eclipses that of any other state. 
    • “A press release this afternoon from the Pennsylvania Department of Health (DOH) said that an unvaccinated resident in Montour County, located in east-central Pennsylvania, tested positive for measles and has died. No other information was given, with DOH citing privacy for the deceased. 
    • “It is the state’s seventh measles-associated death this year.” * * *
    • “To Pennsylvania’s west, cases in Ohio increased by 61 infections this week, bringing the state’s 2026 total to 372. But West Virginia, which borders both Ohio and Pennsylvania, has had just two reported cases for all of 2026.
    • “Unlike most states, West Virginia does not allow religious or philosophical belief exemptions for compulsory school vaccines. This has resulted in higher vaccination rates—CDC data show an estimated 98.9% of kindergartners received the MMR vaccine for the 2025-26 academic year.” 
  • and 
    • “Congenital syphilis rates among US newborns increased nearly sixfold from 2012 to 2022, according to a study published yesterday in Clinical Infectious Diseases. The data show rising rates across all demographics and income levels, with the sharpest increases among Native Americans. 
    • “Congenital syphilis occurs when a pregnant woman with untreated syphilis passes the infection to her baby. The infection can cause organ damage, skeletal abnormalities, neurodevelopmental impairment, stillbirth, and infant death.
    • “For the study, researchers from Johns Hopkins University analyzed hospital records representing 14.6 million birth hospitalizations in 2012, 2016, 2019, and 2022, including an estimated 6,560 newborns diagnosed as having congenital syphilis.
    • “The team found that congenital syphilis rates increased from 16.0 per 100,000 birth hospitalizations in 2012 to 94.7 per 100,000 in 2022, a 5.9-fold increase. The estimated number of affected newborns rose from 597 to 3,325 over that period.”
  • Health Day tells us,
    • “Ever start to fall asleep — and suddenly jolt awake?
    • “It’s called a “sleep start,” or hypnic jerk. And new research links frequent episodes to anxiety and poor sleep.
    • “Researchers surveyed nearly 200 adults and found those experiencing jolts at least once a week reported worse sleep quality, more insomnia symptoms and higher levels of anxiety and depression.
    • “Participants reported more episodes during periods of emotional stress. Those with more negative thoughts about sleep also tended to startle awake more often.
    • “Sleep starts are much more than a simple muscle twitch when falling asleep,” said lead author Tanja Grünberger, from Paris Lodron University in Salzburg, Austria.
    • “Participants described sensations of falling, racing hearts, flashes of light, even loud bangs — sometimes accompanied by fear or panic.
    • “Most drifted back to sleep quickly, but some experienced real distress.”
  • The American Medical Association offers a rerun of its October 10, 2025, post about what doctors want patients to know about getting a good night’s sleep.
  • The New York Times points out,
    • “5 Muscles to Strengthen as You Age
      • “We all know we need to strength train to move well and feel strong. But which exercises are the most important?”
  • Beckers Hospital Review informs us,
    • “About six years ago, Northwell Health launched a school mental health pilot on Long Island with the goal of meeting children where they are, according to Scott Falkowitz, DO, a child and adolescent psychiatrist and medical director of the Northwell School Mental Health Program. 
    • “Today, the New Hyde Park, N.Y.-based system partners with school districts across Long Island and Westchester County. Its behavioral health center in Mount Kisco, N.Y., saw more than 1,100 new pediatric patients in its first year. Only nine were referred to an emergency department.
    • “The need behind that work is broad: Dr. Falkowitz noted that about 1 in 5 young people have a mental health condition that significantly impairs their functioning.
    • “For far too long, the emergency department has been the primary entry point in so many communities where accessing child and adolescent mental health services is in some places — and many places — literally impossible,” Dr. Falkowitz said. “For people who are in a behavioral health crisis, stepping into a loud, chaotic emergency department where there are traumas going on around you, where people are asking you the same question multiple times — you’re ultimately walking away with some guidance, but that important piece of making the connection to outpatient services is often missing.”
    • “Under the partnership, a school counselor or psychologist with a student in crisis no longer has to default to an ambulance ride to the ED. Instead, the student can go to one of Northwell’s behavioral health centers.”

From the U.S. healthcare business and artificial intelligence front,

  • Modern Healthcare reports,
    • “Most major health insurers beat Wall Street expectations for their medical loss ratios in the third quarter.
    • “Cost inflation has moderated from COVID-19 pandemic-era highs.
    • “Oscar Health’s and Clover Health’s medical loss ratios improved the most during the third quarter.”
  • and
    • “Mayo Clinic named Dr. Matthew Callstrom its next president and CEO, succeeding Dr. Gianrico Farrugia who will retire at the end of the year.
    • “Callstrom is the medical director for Mayo Clinic’s systemwide strategy and AI programs.”
  • Beckers Hospital Review relates
    • “During his Nov. 5 fireside chat at Becker’s CEO+CFO Roundtable, Mark Cuban urged health system leaders to point AI at their contracts and ask: “Where are they ripping me off?”
    • “At Columbia, Mo.-based MU Health Care, that work is already underway, CFO Greg Damron said, speaking on a panel later that day. He said the system’s payer contracting team has become one of its leading adopters of the technology.
    • “I think that’s been out of necessity trying to be able to ingest these large payer contracts, find all of the loopholes and dodges that are in there, all the policy updates,” Mr. Damron said.”
  • and
    • “Chicago-based CommonSpirit recorded an operating loss of $544 million (-5.3% operating margin) before special charges in the first quarter of fiscal 2027, which ended Sept. 30, according to its Nov. 13 financial report.”
  • Fierce Health points out
    • “Ardent Health is acquiring Boone Health, a mid-sized nonprofit system based in Columbia, Missouri, for $47 million in cash, the organizations announced Thursday. It marks Ardent’s first entry into the Missouri healthcare market.
    • “The deal, expected to close in the first quarter of 2027, includes a 10-year, $200 million capital commitment on nonprofit Ardent’s part. That money will be invested in Boone’s facilities, workforce and, in the near term, an expansion of its emergency department, according to the announcement. 
    • “Ardent has agreed to maintain Boone’s essential hospital services while developing its 392-bed regional referral center, Boone Hospital Center. It also plans to maintain employment for existing Boone employees and providers, continue its charity care policy and establish a local advisory board.” 
  • The Wall Street Journal tells us
    • “When CVS Health CVS said last week it would spin off its 9,000 drugstores, nobody cheered.
    • “Critics of healthcare consolidation called it a political decoy that leaves the conflicts of vertical integration at the insurance conglomerate untouched. Wall Street had a different gripe: the pieces might be worth less apart. The stock lost some $15 billion in market value when the breakup was announced.
    • “But selling pills and sunscreen out of labor-intensive stores is a very different business from managing drug benefits at Caremark, insuring patients at Aetna or dispensing specialty drugs. And the strategic advantages of owning those stores have diminished. If they no longer give the rest of CVS a meaningful edge, splitting them up might leave investors better off—even if it does nothing to appease lawmakers. * * *
    • “Investors assumed the worst. Some feared the lost benefits of common ownership—lost synergies, in Wall Street parlance—could top $1 billion a year. At a Wolfe Research investor conference this week, CVS Chief Executive David Joyner said an analyst’s estimate of about $500 million a year was “much closer” to CVS’s own models. That helped lift the shares, though they are still trading slightly below where they stood before the Nov. 4 announcement. Whether existing contracts between the stores and pharmacy-benefit manager Caremark stay in place over the long term is another matter.
    • “Regulation has steadily eroded the advantages of owning drugstores, Joyner said in an interview. Caremark’s benefit designs once drew members to CVS counters, but many states have moved to restrict such arrangements, and some have moved to ban common ownership of pharmacies and pharmacy-benefit managers, or PBMs, outright. So why keep a capital-intensive, slow-growing political headache?”
  • Fierce Pharma informs us,
    • “Over the last week, oral obesity medicines continued their upward trajectory, with both Eli Lilly’s Foundayo and Novo’s Wegovy pill scripts climbing to new heights.  
    • “Foundayo, in its 31st week since launch, saw its best uptake yet with 69K scripts—a  7% week-over-week jump—according to notes from Citi and Jefferies citing data from IQVIA. But Lilly’s oral option is still well behind Novo’s Wegovy pill launch pace, which hit 163K scripts at week 31 of its own rollout.  
    • “According to Jeffries, Foundayo is now making up for roughly 40% of new oral obesity prescriptions and 45% of the U.S. oral market’s incremental growth. Meanwhile, competition between the two metabolic rivals is expanding geographically as Lilly and Novo continue to launch their obesity pills into new markets.  
    • “For Novo’s part, week 42 of the Wegovy pill launch saw prescriptions climb slightly to 185K. Jeffries attributed a 72.8% overall oral market share to the Danish pharma’s pill, with Foundayo holding the remaining 27.2%.” 

Thursday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC

  • Govexec points out,
    • “A lame-duck Congress is suddenly hastening the process to find a new long-term leader of a governmentwide watchdog agency that has drawn the ire of the Trump administration. 
    • “House and Senate Republicans faced calls over the past two years to start the bipartisan process of interviewing candidates to lead the Government Accountability Office. 
    • “Under the current process, the selection of the GAO comptroller general begins with a commission of 10 senior House and Senate lawmakers from both parties that recommends individuals for the position to the president. 
    • “Whoever the president selects is subject to Senate confirmation for one nonrenewable 15-year term. The last time lawmakers vetted candidates for GAO’s top job in 2010, the congressional commission spent more than a year on its search. 
    • “This time around, members of the commission are being given a single day to come up with candidate recommendations, after receiving notice on Veterans Day. The commission is meant to recommend at least three candidates for the job.” * * *
    • “The Washington Sun reported last month that the Trump administration is floating the idea of having Office of Management and Budget Deputy Director Eric Ueland serve as the next GAO comptroller general. The HSGAC aide said the committee is aware that Ueland’s name has been floated for the job. 
    • “Ueland said Monday at an industry conference that the Trump administration’s reshaping of the federal government has been “long overdue.” * * *
    • “The Senate in May 2025 voted 52-45 along party lines to confirm Ueland as OMB’s second-in-command. A potential vote to confirm him as GAO comptroller could come down to a few outgoing Republican senators who have challenged some of the Trump administration’s decisionmaking. 
    • “The comptroller general position opened up in December 2025 when Gene Dodaro retired. Orice Williams Brown, the agency’s chief operating officer, is currently leading GAO in an acting capacity.” 
  • Beckers Health IT reports,
    • “CMS is extending its nationwide freeze on new Medicare enrollments for hospice and home health agencies for an additional six months as part of its efforts to combat fraud, waste and abuse.
    • “The agency announced the initial six-month moratorium May 13 and said in a Nov. 12 news release that the conditions prompting the restrictions have not sufficiently improved to lift them.
    • “The extension will continue to prohibit new Medicare enrollment applications and certain changes in majority ownership for hospice and home health providers nationwide.
    • “However, CMS is modifying the restrictions to allow currently enrolled hospices and home health agencies to add new practice locations under their existing Medicare enrollments. The original moratorium prohibited these additions.
    • ‘The extension will not affect existing Medicare enrollments or prevent currently enrolled providers from continuing to deliver services.”
  • Beckers Behavioral Health relates,
    • “Mark Cuban Cost Plus Drug Co. will lead research teams laying the groundwork for a domestically manufactured ibogaine product, part of an HHS effort to develop the psychedelic as a potential treatment for post-traumatic stress disorder and other serious mental illnesses, including among veterans.
    • “HHS committed up to $4.9 million to the effort through the Advanced Research Projects Agency for Health, the department announced Nov. 12. The Cost Plus-led teams will build the regulatory, clinical, chemical and engineering foundation for a single-molecule ibogaine hydrochloride product. Separately, Beond will generate clinical data on the drug’s safety, dosing, efficacy and durability. All awardees will make their research data open source.
    • “HHS Secretary Robert F. Kennedy Jr. unveiled the awards alongside Department of Veterans Affairs leaders the day after Veterans Day. The funding will support investigational new drug applications for future U.S. clinical trials, secure clinical-grade ibogaine and build domestic manufacturing processes.”
  • The American Hospital Association News tells us,
    • “The AHA Nov. 12 published a new issue brief, Advancing Health Literacy in Hospitals and Health Systems, that examines gaps within health literacy and highlights examples of organizational strategies used by hospitals. This resource is designed to help hospital leaders, clinical staff and community health partners build a comprehensive, system-level approach to improving health literacy. LEARN MORE” 

From the U.S. Office of Personnel Management front,

  • Federal News Network interviews OPM’s Associate Director for Health Caren and Insurance Matt Kiley about the ongoing Federal Benefits Open Season. Check it out.
  • Govexec discusses
    • “What retirees should know about health insurance during Open Season
      • “Federal retirement benefits expert Tammy Flanagan and Executive Editor Tanya Ballard Brown discuss what federal employees nearing retirement and current retirees should consider when choosing health coverage during Open Season.”
  • Per an OPM Federal Register notice,
    • OPM is extending the current suspension of applications for coverage in FLTCIP in light of ongoing volatility in long term care costs and a greatly diminished insurance market. The original suspension notice was published at 87 FR 69345 (November 18, 2022) and suspended FLTCIP applications for 24 months, as authorized by 5 CFR 875.110. The suspension was extended through a second notice for an additional 24 months, published at 89 FR 89662 (November 13, 2024).
    • This extension, which will take effect on December 19, 2026, complies with the requirements of § 875.110(d), which requires OPM to issue a Federal Register notice at least 30 days before the end of the suspension period in order to effectuate another suspension not to exceed 24 additional months. As with the current suspension period, no applications for FLTCIP coverage will be accepted during the extension period, and current enrollees may not apply to increase their coverage. The enrollment status or benefit eligibility of current enrollees will not change due to the suspension. For those in a claim status, there is no change to coverage and the claims reimbursement process.

From the U.S. Food and Drug Administration front,

  • Cardiovascular Business reports
    • “California-based Tandem Diabetes Care is recalling more than 80,000 insulin pumps due to a risk of false-positive occlusion alarms. The recall includes several models of the company’s Tandem Mobi Insulin Pumps, which are battery-operated devices that provide both long-acting and short-acting bolus insulin doses.
    • “Unlike many recalls, these devices can still be used for patient care. Tandem Diabetes care has provided specific recommendations patients should follow going forward to avoid any risk.”
  • Beckers Hospital Review relates,
    • “The FDA has shelved the Commissioner’s National Priority Voucher program, which former Commissioner Marty Makary launched in 2025 to cut drug review times to one to two months, according to a Nov. 12 Reuters report citing six sources and internal documents. HHS disputes that characterization, saying the pilot is ongoing.
    • “No new drugs have received a voucher since Dr. Makary left the agency in May, and an executive council of political appointees that oversaw the reviews has gone dormant, Reuters reported. Of the 22 drugs given a voucher, a dozen have been approved, including five since Dr. Makary’s departure. For several drugs, the program sped approval by eight months or more, according to the report.
    • “One source told Reuters that FDA leadership told companies the agency is not moving forward with the program but is keeping applications open, and that applications submitted now do not advance. For the nine drugs still in the program, career scientists have resumed overseeing review timelines, two sources said.
    • “HHS spokesperson Emily Hilliard said the pilot is ongoing and that the FDA is reviewing feedback from a June public hearing to refine the framework, according to Reuters. The agency did not respond to questions about the departure of the program’s lead or whether a new coordinator has been named.”

No Surprises Act News

  • Beckers Payer Issues reports,
    • “Researchers at the USC Schaeffer Institute argued Nov. 6 that Congress should preserve the NSA’s consumer protections while making targeted fixes to arbitration rather than scrapping it, as the Pallone bill and the Paragon proposal would each do in different ways. The piece recommended letting arbitrators pick any value within the range of the two offers instead of the current baseball-style format, scaling arbitration fees to the value of disputes, and strengthening eligibility screening so arbitrators have no financial incentive to let ineligible claims proceed.” 
  • Fierce Healthcare adds,
    • “The No Surprises Act’s independent dispute resolution process cost employer plans $8.39 billion in 2025, according to a new analysis.
    • “Researchers at the Employee Benefit Research Institute combed federal IDR data and found that these additional costs equal about 63 cents per $100 spent by employer-based insurance plans. The total includes $4.73 billion in costs incurred in the first half of the year as well as $3.66 billion in the second half of 2025.
    • “Even when EBRI analysts used different thresholds to exclude outlier awards, such as a costs that were unusually high, they still landed on an estimate of at least $8.02 billion, per the study.
    • “The researchers note that this data doesn’t necessarily paint the full picture, as it only encompasses cases that proceeded to IDR. The study doesn’t include information on claims that were settled outside of arbitration, administrative costs, any changes in networks or provider rates or the cost associated with patient protections.”

From the public health and medical / Rx research front,

  • Beckers Clinical Leadership reports,
    • “The share of U.S. deaths attributed to flu in the last week of October was higher than in any comparable week of the past decade, according to preliminary CDC data.
    • “In the week ending Oct. 31, 0.3% of all deaths were due to flu, according to the agency’s latest FluView report. That share held stable from the week before but has trended upward over the past seven weeks. It is nearly double the next-highest weekly figure of the past 10 seasons (0.16% in 2022-23) and well above the 0.02% to 0.08% recorded in most other recent seasons.
    • “The early climb tracks with broader flu activity, which the CDC said is higher than typically seen this time of year. Still, the agency cautioned that an earlier rise does not necessarily mean a higher peak or a more severe season, and its preliminary assessment rates the season’s severity as low across all age groups so far.
    • “Early-season deaths also typically make up a small share of total seasonal mortality, as flu deaths generally climb through January and February.
    • “The CDC estimates at least 1,400 flu deaths nationwide so far this season, along with 1.7 million illnesses and 25,000 hospitalizations. Three pediatric flu deaths have been reported for the 2026-27 season.”
  • Healio relates,
    • “MMR vaccination normally occurs at ages 12 to 15 months and 4 to 6 years. 
    • “Pediatricians can recommend an earlier dose based on other risk factors, such as a nearby outbreak.” * * *
    • “Adam Ratner, MD, MPH, FAAP, a member of the American Academy of Pediatrics’ Committee on Infectious Diseases, said there are many states with overall vaccination rates of 93% to 94% but school districts with rates that are many percentage points lower.
    • “That is meaningful because if you get someone who travels, gets measles and comes back and gives it to someone in that community, then that becomes a place where a measles outbreak can happen,” Ratner told Healio.
    • “This is an example of a scenario in which pediatricians and parents might discuss an early dose of MMR vaccine for an infant, based on the CDC recommendation that it can be given between 6 and 11 months in situations where there is ongoing spread of measles in the community.”
  • The Wall Street Journal tells us,
    • “The American Cancer Society recommended that middle-aged men get screened regularly for prostate cancer.
    • “The new guidelines recommend that men aged 50 to 69 receive a prostate-specific antigen blood test every two years.
    • “Men at high risk, including Black men, should receive an annual PSA-based screening starting at age 45.” * * *
    • “For years, the nation’s largest cancer-fighting organization advised men to decide with their doctors whether to test for prostate cancer. Widespread testing in the late 1980s and 1990s led to overtreatment and damaging side effects for many men, raising questions about the benefits of testing.
    • “The cancer society changed its guidance because there is now more evidence that PSA-based screening saves lives and there are better tools to prevent treating the wrong patients, said Robert Smith, director of the cancer society’s Center for Early Cancer Detection and senior author of the guidelines. The hope is also to stem the increase in diagnoses of late-stage prostate cancer. He pointed to data from a more than two-decade-long study in Europe that found 13% fewer deaths among men ages 55 to 69 who received regular PSA tests.”
  • Cardiovascular Business informs us,
    • “Semaglutide is sold by Novo Nordisk under the brand names Wegovy and Ozempic, and dulaglutide is sold by Eli Lilly and Company under the brand name Trulicity. Tirzepatide, meanwhile, is a popular dual GIP and GLP-1 hormone receptor agonist sold by Eli Lilly and Company under the brand names Mounjaro and Zepbound.
    • “What stood out across the class was that subcutaneous semaglutide was the only agent associated with a significant reduction in AFib, while tirzepatide—which usually outperforms it on weight and glucose—ranked lower, and dulaglutide was linked to more AFib,” co-authors Lucas M. Barbosa and Vinícius Martins Rodrigues Oliveira, MD, told Cardiovascular Business. Barbosa is with the Federal University of Minas Gerais in Brazil, and Oliveira is with the Federal University of Goiás in Brazil.” * * *
    • “Click here to read the full study.”
  • The New York Times lets us know,
    • “It’s not every day that a 76-year-old woman is asked to talk nonsense — repeating “ga ba da” and “ka pa ta” as fast as she can.
    • “All with sensors affixed to her tongue, forehead, chin, jaw, upper and lower lip recording her tiniest muscle movements in the name of science.
    • “The goal is to analyze changes in people’s speech to try to predict their likelihood of developing dementia and track shifts in their brain health.
    • “We are seeing differences that humans can’t see or can’t really detect by their ears, but it’s there years and years before cognitive decline,” said Marziye Eshghi, the researcher leading the effort at Mass General Brigham University of Health Professions in Boston.
    • “Dr. Eshghi’s project measures about 130 different speech-related features in participants like the 76-year-old woman from suburban Boston, who asked to be identified by her first name, Deb, to protect her privacy. The data is run through artificial intelligence algorithms and compared with known biological risk factors for Alzheimer’s. In preliminary results, speech-related data was better than cognitive testing at identifying Alzheimer’s risk in cognitively unimpaired older people, Dr. Eshghi’s team reported.”
  • Health Day adds,
    • “Nearly half of U.S. adults say they’re more anxious this year than last, a recent poll finds
    • “Regular exercise, even short walks that add up over the day, may help ease anxiety and depression
    • “Sleep, nature, healthy eating and less social media scrolling can also lift mood, experts say.”
  • Per STAT News,
    • “A massive scientific collaboration meant to unravel the mysteries of the human brain has produced the most detailed map yet of the basal ganglia, a region closely associated with a wide array of psychiatric and neurologic disorders.
    • “Researchers profiled more than 25 million cells, generating a deluge of data that allowed them to generate a “parts list” of what cells are present in the basal ganglia and how they’re arranged. In the process scientists discovered a new type of neuron that appears to play a role in schizophrenia. They also identified cell types linked to depression, bipolar disorder, and post-traumatic stress disorder.
    • “Demonstrating the value of the work, the scientists produced preliminary evidence that they can use their more detailed understanding of brain cell types to deliver therapies with increased precision. Authors working in mouse models of Parkinson’s disease showed that a gene therapy designed to work in a subset of basal ganglia cells was as effective as a blanket approach; it was also safer.
    • “These and other related findings were published across more than two dozen studies on Thursday in a special issue of the journal Cell. The cellular map is the outcome of hundreds of scientists working in concert across nine countries and more than 50 institutions. Researchers liken the scale and ambition of this work to the Human Genome Project, and one of their goals is to generate a map of the whole brain, which contains around 100 billion neurons and just as many other cells that play supportive roles.”

From the U.S. healthcare business and artificial intelligence front,

  • The Wall Street Journal reports,
    • “Germany’s Merck MRK KGaA raised its annual guidance for the third time this year after reporting top-line growth across its three businesses.
    • “The Darmstadt, Germany-based conglomerate has moved to reshuffle its portfolio, which spans life-science tools and services, pharmaceuticals and chemicals, since Kai Beckmann became its chief executive officer earlier this year, when Belen Garijo left for Sanofi.
    • “The company said Thursday that its latest guidance increase—which follows earlier upgrades alongside its earnings for the first and second quarters—reflected improvements in its underlying performance as well as favorable currency movements, and attributed its third-quarter results to the strength of its integrated business model.”
  • Beckers Hospital Review relates,
    • “Duluth, Minn.-based Essentia Health’s credit rating was upgraded to “A” from “A-” by Fitch. 
    • “The upgrade reflects the system’s leading market position across its three-state service area and improved financial flexibility, Fitch said in a Nov. 11 report. 
    • “The credit agency said it expects Essentia’s operating EBITDA margins to improve moderately over the medium term, driven by retail and specialty pharmacy growth, improved length of stay and throughput, workforce efficiency and expanded access. Fitch added that a manageable capital plan and easing leverage should continue to strengthen the system’s balance sheet.
    • “On Sept. 29, Essentia and Bloomington, Minn.-based HealthPartners announced plans to combine to form a 22-hospital nonprofit health system with more than 135 clinics and 6,000 clinicians. The combined organization will operate as HealthPartners and employ about 45,000 people. Essentia Health facilities will retain the Essentia name as operations are integrated. The transaction is expected to take effect Jan. 1, pending regulatory approvals. Fitch said it views the proposed transaction as neutral to Essentia’s rating.” 
  • Beckers ASC Review tells us,
    • “Health systems have bought independent practices in orthopedics, family medicine, women’s health and dermatology this fall. One of the deals came out of a bankruptcy auction, and another is being challenged in court.
    • “[The article discusses] five deals involving an independent practice acquired by a health system that Becker’s has reported on since Sept. 1, 2026.”
  • Modern Healthcare explains “why independent physicians opt for ‘umbrella mergers’”.
    • “An umbrella merger is when a group of independent physician practices combine under a single corporate entity.
    • “Umbrella mergers give physicians access to more resources and create leverage in contract negotiations, while still maintaining some autonomy.
    • “The model is not a quick fix for struggling practices and requires a time commitment to build a leadership structure and establish protocols.”
  • Healthcare Dive informs us,
    • “Physicians’ AI use is moving beyond administrative tasks to more everyday clinical decision support, like searching through medical literature, according to a survey published Thursday by Doximity. 
    • “More than half of physicians said they use AI daily and another third use it at least once a week, the medical professional and technology firm reported. Most physicians also said that AI has taught them clinical knowledge they didn’t already know.
    • “Still, physicians remained concerned about AI eroding their skills, with more than half saying they specifically worry about how AI use will impact the development of residents, fellows or trainees they supervise.”

Tuesday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington DC,

  • Roll Call reports that the Republicans in Congress reelected Sen. John Thune (R SD) as their minority leader in the next Senate and elected Jim Jordan (R Ohio) as their minority leader in the next House of Representatives. The new Congress will gavel in on January 3, 2026.
  • The Senate Judiciary Committee announced that it will be holding a full Committee hearing about “Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs” next Tuesday November 17.
  • The American Hospital Association relates,
    • “The Centers for Medicare & Medicaid Services has allocated 200 Medicare-funded residency slots to 99 teaching hospitals. The slots are the fifth allocation from 1,000 new residency positions authorized under Section 126 of the Consolidated Appropriations Act of 2021. No more than 200 full-time slots can be awarded per year.” 
  • FedWeek tells us,
    • “The Postal Service has said it cut 19 million work hours in fiscal 2026 as it continued consolidating its processing and transportation networks, but compensation and benefits costs still rose by $456M over 2025.
    • “Overall the USPS reported a $6.5 billion loss on the year – while that was down from $9 billion in fiscal 2025, much of the change was due to a non-cash accounting change in workers comp rather than lower labor costs, while suspended payments toward pensions freed up cash. (The USPS inspector general reported in October that the Postal Service faces a $104 billion retirement funding shortfall.)
    • “Key findings for fiscal 2026: 
      • “Revenue up, volume down. Shipping and packages revenue increased 5.1 percent on 5.3 percent lower volume, while marketing mail revenue rose 5.3% and first class mail rose 1.2%, both on lower volumes. USPS cited growth in Ground Advantage shipping and price increases.
      • “Workers comp expenses fell $2.4 billion, reflecting a non-cash actuarial revaluation of existing cases and changes in discount rates.
      • “Total operating expenses fell by $404 million, but other operating expenses rose $894 million, retiree health benefits $726 million, compensation and benefits $456 million and transportation $225 million. Retirement expenses fell $277 million.”
  • The Wall Street Journal informs us,
    • “The Trump administration last year came up with a plan to combat high drug prices—making European governments pay more. 
    • “The result so far: still-high drug prices in the U.S. and fewer new drugs in Europe. 
    • “There has been a 27% drop in new drug releases across European countries over the last 17 months, compared with the same period before President Trump announced the plan, according to new data from market-research firm GlobalData. Meanwhile, drug approvals in Europe have held steady over that time period.
    • “You have companies saying, ‘Well maybe I won’t enter the market there because it’s just going to be used against me in the United States,’” said Ipsita Smolinski, director of health-policy research firm Capitol Street.”

From the U.S. Office of Personnel Management front,

  • Federal News Network reports,
    • “Following a couple years of uncertainty, the Office of Personnel Management has opted to continue the Combined Federal Campaign for the 2026 donation cycle.
    • “The CFC has been an annual donation campaign for more than 60 years, allowing federal employees to contribute to thousands of charities worldwide via payroll deductions. But citing high overhead costs and dwindling participation, OPM was recently considering shuttering the program altogether.
    • “After making several changes meant to reduce administrative costs, OPM Director Scott Kupor confirmed this week that the CFC will continue for the 2026 campaign. Federal employees can make donations between Dec. 1, 2026, and Feb. 19, 2027.
    • “Historically, the program deprived hardworking and generous donors of their intended charitable contributions by wasting close to $0.50 of every dollar donated on administrative overhead,” Kupor said in a statement to Federal News Network. “For 2026, OPM has dramatically reduced this cost while it continues to consider whether the program remains viable for subsequent years.”
  • FedWeek relates,
    • “The number of federal employees teleworking in fiscal 2025 fell from 40 percent to just 12 percent, with a drop in the number of teleworkers falling 73 percent (1,017,230 to 273,497) following President Trumps “Return to In-Person Work” memo issued on his first day in office, according to new OPM report to Congress.
    • “The report covers just the final pay period of fiscal 2025, not the entire year, but OPM director Scott Kupor said in the introduction that the sample is enough to reflect change in agency practices that took place after the EO. “This is a fundamental reset of how the Federal workforce shows up every day to serve the public,” said Kupor, adding that telework remains a legitimate tool but should be the exception not the norm.”
  • FedSmith tells us,
    • “Streak Snapped: OPM Retirement Backlog Rises for the First Time Since February
      • “The OPM retirement backlog rose 20% in October 2026, but a closer look at the data shows why that is not as ominous as it sounds.”

From the U.S. Food and Drug Administration front,

  • Fierce Pharma reports,
    • “Merck KGaA just secured an FDA approval for its new once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, adding to a growing list of regulatory checkmarks around the globe. 
    • “The agency has approved pimicotinib, under the commercial moniker Pimjetmi, to treat symptomatic tenosynovial giant cell tumor (TGCT), a rare and non-cancerous, locally aggressive tumor that grows in or around the lining of the joints. Pimjetmi is specifically indicated in adults for whom surgical resection of the tumor would cause functional imitation or severe morbidity. 
    • “The FDA decision hinged on Merck KGaA’s phase 3 Maneuver trial and follows similar approvals from regulators in China, Canada and Switzerland.” 
  • MedTech Dive relates,
    • “The Food and Drug Administration granted de novo authorization to Virtuoso Surgical’s robotic system for endoscopic surgery to remove bladder tumors, the company said Tuesday.
    • “In Virtuoso’s procedure, lesions are removed in one piece in an approach called en bloc resection to obtain tissue for diagnosis of bladder cancer. Two miniaturized robotic arms at the tip of a standard-sized endoscope operate through the urethra, without incisions.
    • “The robot, which received breakthrough device designation in September 2025, is the first device in a new FDA classification for electromechanical surgical systems used in endoluminal procedures, where instruments pass through an endoscope into the body.”

No Surprises Act News

  • The American Hospital Association News reports,
    • “The departments of Health and Human Services, Labor, and the Treasury announced today that Physio Solutions, LLC, a recently certified independent dispute resolution entity, is now available to adjudicate disputes submitted for the federal IDR process. The organization was added in September, bringing the total to 17 entities. IDR arbitrators help make payment determinations in disputes between providers and health insurance issuers under the No Surprises Act.” 

From the judicial front,

  • Modern Healthcare reports,
    • “Carelon Behavioral Health will pay more than $10 million to settle state claims that it kept inaccurate provider directories and wrongly denied coverage for substance-use treatment, leaving New Yorkers without care. 
    • “The state attorney general’s office on Tuesday announced two settlement agreements with Carelon, a Boston-based subsidiary of insurer Elevance Health, to resolve investigations into its business practices. The investigations found that Carelon maintained so-called “ghost networks” — provider directories that failed to list clinicians accepting in-network patients — and unlawfully rejected patients’ claims for addiction services. As a result, patients experienced delays in receiving care and paid out-of-pocket costs, the attorney general’s office said.” * * *
    • “Carelon did not admit or deny wrongdoing in the settlements.”

From the public health and medical / Rx research front,

  • The New York Times reports,
    • “Measles is once again endemic — a constant and predictable presence — in the United States, 26 years after it was declared eliminated in the country, an analysis of genetic data from outbreaks of the disease has found.
    • “Data from the outbreaks will be the focus of deliberations by an international panel of scientific experts convening on Tuesday to decide whether the United States should lose its official designation as a nation that has eliminated measles. An announcement of the decision is expected on Nov. 17.”
  • Harvard Health Online relates,
    • “To prevent a heart attack, stroke, and cognitive decline, aim for a blood pressure reading below 130/80 mm Hg — and ideally less than 120/80 mm Hg. That’s according to the current blood pressure guidelines from the American Heart Association (AHA) and American College of Cardiology.
    • “Nearly half of adults in the United States have blood pressure readings of 130/80 mm Hg (the threshold for stage 1 hypertension) or higher (see “Blood pressure categories”). Lifestyle changes can help reduce blood pressure, but if you don’t reach your goal after three to six months, it’s time to start medication, says Dr. Randall Zusman, director of the Division of Hypertension at the Harvard-affiliated Massachusetts General Hospital Heart Center.
    • “People with stage 1 hypertension are twice as likely as people with normal blood pressure to have a heart attack or stroke,” says Dr. Zusman. As the 2025 guideline now points out, high blood pressure is also strongly linked to a higher risk of cognitive decline and dementia, he adds.” * * *
    • “The guidelines also feature detailed advice about blood pressure treatment, which includes four classes of drugs deemed first-line options: ACE inhibitors, angiotensin-receptor blockers (ARBs), calcium-channel blockers, and diuretics.”
  • Health Day tells us,
    • “Radon gas is already known to cause cancer, but a new study suggests it may also affect heart health.
    • “Older women appear to have a higher risk of heart failure if they live in areas with higher indoor radon levels, researchers reported Nov. 5 in JAMA Network Open.
    • “Women past menopause are more likely to both develop heart failure and die from the condition if exposed long-term to high radon levels, researchers found.
    • “If confirmed, these findings suggest that ridding your home of radon could have heart health benefits “analogous to the once-unrecognized benefits of smoking cessation, long before cigarette and environmental tobacco smoke were identified as risk factors for non-pulmonary disease,” senior researcher Dr. Eric Whitsel said in a news release.” 
  • Healio informs us,
    • “Adults with moderate to severe obstructive sleep apnea and overweight or obesity who used the oral GLP-1 orforglipron for 1 year experienced improvements in sleep apnea severity, according to results from the ATTAIN-OSA trials.
    • “Orforglipron (Foundayo, Eli Lilly) also conferred improvement in various cardiometabolic parameters, including weight, high-sensitivity C-reactive protein and blood pressure, researchers reported at the American Heart Association Scientific Sessions.
    • “These data support the potential use of orforglipron as a promising oral treatment option for moderate to severe obstructive sleep apnea in adults with obesity or overweight,” Vaishnavi Kundel, MD, MSc, associate professor of medicine and program director of the sleep medicine fellowship at Icahn School of Medicine at Mount Sinai, said during a press conference.”
  • The American Medical Association lets us know,
    • “Question: What is the association of GLP-1RA use and the development or progression of age-related macular degeneration (AMD) compared with other weight loss drugs for patients with overweight or obesity? 
    • “Findings: In this cohort study of 91,408 patients, GLP-1RA use was associated with a reduced risk of developing nonexudative AMD but showed no association with progression to exudative AMD. 
    • “Meaning: These findings suggest that GLP-1RAs may offer ocular benefits compared with other weight loss drugs, supporting further investigation in prospective, randomized studies.
    • ‘A JAMA Ophthalmology invited commentary published with the study lends perspective on the findings. “Will health care professionals prescribe these medications because they lead to a decreased risk of AMD? Or stop them because they may increase the risk of exudative AMD?” the commentary asks. While physicians “should keep these risks (or benefits) in mind, they seem ancillary to the overall health benefits of these medications.”
  • Per Radiology Business,
    • “Experts are sharing some key lessons learned from a pilot program that integrated both breast and lung cancer screening, seeking to boost adherence for the latter.
    • “Lung cancer remains the leading cause of cancer death in the U.S., with fewer than 16% of eligible adults undergoing lifesaving low-dose CT surveillance. Conversely, breast cancer screening (BCS) reaches nearly 80% of eligible women, with many individuals dying of lung cancer despite attending routine mammography, experts write in JACR. 
    • “St. Louis-based Washington University’s School of Medicine has aimed to address this challenge. It’s “Pink and Pearl” pilot program has done so by leveraging strong BCS attendance to identify lung cancer screening (LCS)-eligible women during their routine mammography visit. 
    • “Named for the breast (pink) and lung (pearl) cancer awareness ribbons, P&P uses established, trusted BCS visits as a ‘teachable moment’ for lung health discussions with women who may not otherwise be reached,” lead author Beryne Odeny, MD, MPH, PhD, an assistant professor of surgery at Washington University, and colleagues wrote Nov. 7. “Early studies demonstrate improved LCS uptake in eligible patients identified during BCS.” 
  • Per Fierce Pharma,
    • “Johnson & Johnson is gearing up to expand the commercial reach of Caplyta after scoring a second phase 3 victory in bipolar mania.
    • “The second phase 3 trial evaluating Caplyta (lumateperone) for treating manic episodes in patients with bipolar I disorder met its primary endpoint, showing a statistically significant improvement in manic symptoms compared with placebo at week 3, J&J said Tuesday.
    • “Key secondary endpoints, such as overall illness severity at week 3, were also met. And the drug’s tolerability profile was consistent with prior studies, J&J said.”
  • Per BioPharma Dive,
    • “Beam Therapeutics said Tuesday that a precision gene editing treatment it’s been working on succeeded in a pivotal trial, helping free people with sickle cell disease from the severe bouts of pain associated with their condition. 
    • “The results for ristoglogene autogetemcel, or “risto-cel,” represent the first positive late-stage readout for a drugmaking approach known as “base editing.” Beam says it plans to submit an approval application to the Food and Drug Administration by as soon as the end of the year.
    • “Sickle cell disease, a genetic disorder largely affecting people with African ancestry, is already the target of two marketed genetic therapies called Casgevy and Lyfgenia, both of which initially saw slow uptake. Those treatments, however, are built on different underlying technologies.”

From the U.S. healthcare business and artificial intelligence front,

  • Per a Health Care Cost Institute post in LinkedIn,
    • “In Managed Healthcare Executive, Peter Wehrwein looks at our new Health Care Cost and Utilization Report. From 2019 to 2023, spending per person with employer coverage rose 18.8%, from $5,676 to $6,743. Prices went up 17.7% over that time, while use of services grew just 1.8%.
    • “Prescription drug spending grew fastest, but hospitals remain the biggest piece. Inpatient and outpatient hospital services made up 46% of spending. HCCI President and CEO Katie Martin told Wehrwein that’s one of the areas where employers should focus if they want to bring costs down.
    • “Read the article: https://lnkd.in/eCFGSYGr
  • Beckers Payer Issues reports,
    • “The nation’s largest insurers spent the third quarter navigating membership losses in their Medicaid and ACA businesses, ongoing medical cost pressures and the continued focus on strengthening margins following a difficult 2025. Six of the seven organizations [discussed i in the article] raised their full-year earnings guidance..”
  • and
    • “Fitch Ratings believes CVS Health’s planned separation will be credit neutral for Aetna Life Insurance Co., the credit rating agency reported Nov. 9.
    • “One company, which will go by CVS Health in the interim, will encompass Aetna, pharmacy benefit manager CVS Caremark, CVS Specialty, primary care centers Oak Street Health and health evaluations business Signify Health. The other company, CVS Pharmacy, will include CVS’ 9,000 retail pharmacies, mail pharmacy, MinuteClinic and technology services business Health100. 
    • “Aetna Life’s current insurer financial strength rating is ‘A’/Negative. Fitch does not expect the split to significantly dampen Aetna Life’s company profile. Despite CVS Health losing some diversification, the parent’s remaining businesses are staying “sufficiently diversified and generally consistent with large health insurance and pharmacy benefit management peers.”
  • Fierce Healthcare relates,
    • “In this year’s third quarter, Kaiser Permanente grew its operating revenues by 9% and more than doubled its operating income compared to the year prior, the organization recently shared. 
    • “The country’s largest nonprofit health system and its subsidiaries logged $34.7 billion in operating revenues and $34.2 billion in operating expenses for the three months ended Sept. 30, 2026, according to a release outlining topline financial numbers. 
    • “Its operating income was $495 million (1.4% operating margin), as compared to the prior year’s $218 million (0.7% operating margin). That’s a bit tighter than the system reported in 2026’s earlier quarters, though the organization often notes that its margins tend to thin out as the year progresses due to health plan enrollment cycles and seasonal expense increases.”
  • and
    • “The University of Texas MD Anderson Cancer Center is expanding its cancer care facilities through the addition of two new buildings—totaling a $3.4 billion investment.
    • “The new facilities, dubbed Inspiration Tower and Prism, will make up nearly two million square feet and allow for MD Anderson to care for nearly 250,000 patients annually, executives say. The expansion is funded by UT MD Anderson and its philanthropic support.
    • “Every detail of these buildings, from the technology to the treatment rooms, was designed around our patients who will receive their care in them and our employees who will work in them,” said Jeffrey Lee, M.D., UT MD Anderson president ad interim, in a statement. “The facilities will serve as a physical representation of hope for the patients and their families who will walk through the doors.”
  • MedCity News discusses
    • “Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
      • “In a panel discussion, executives from Noom, Omada, Virta and Twin Health discussed how they are going beyond the pill in their GLP-1 strategy and responded to a question about whether they will exist two-to-three years from now.” 
  • STAT News adds,
    • “Oura, the smart ring maker that just over a month ago delayed plans to go public over market uncertainty, announced on Tuesday that it will spend $625 million to acquire Counsel Health, a clinical artificial intelligence startup.
    • “Counsel Health is the maker of a chatbot that users can talk with about health concerns before being transferred to a clinician for treatment and diagnosis over telehealth. The company had previously disclosed $36 million in funding. 
    • “The large transaction reflects a growing desire to connect consumer wearable devices to clinical care as well as the conviction that AI chatbots will be an important part of health care.”
  • Beckers Hospital News points out,
    • “Burlington, N.C.-based Labcorp has completed its acquisition of specialty laboratory Millennium Health for $375 million, according to a Labcorp news release. 
    • “The acquisition can be broken into two parts — $245 million payable in cash at closing and up to $130 million of consideration, contingent upon specified future events.
    • “Millennium Health helps clinicians more effectively monitor individuals living with chronic pain, substance use disorders, mental health conditions and other health needs by providing insight into patients’ recent use of prescription medications and/or illicit drugs.”
  • Fierce Healthcare lets us know,
    • “Digital health and wellness company Hims & Hers tightened its full-year 2026 revenue outlook after missing Wall Street analysts’ revenue and earnings estimates.
    • “Andrew Dudum, co-founder, chairman and CEO, pointed investors toward the increasing scale of Hims & Hers’ pharmacy and lab infrastructure. That growth is driving efficiencies for the company, as is its artificial intelligence native experience, he said.
    • “That infrastructure positions us to launch treatments of increasing complexity, including testosterone replacement therapy this quarter and our Peptides Plus offering later this month,” Dudum said.
    • “Peptides have been a focus for the company as of late, with Dudum telling investors last quarterit plans to offer already-permitted peptides, like sermorelin and NAD+.”
  • and
    • “Google launched Tuesday Gemini for healthcare, an agentic artificial intelligence platform aimed at connecting complex clinical, financial and administrative workflows used by healthcare providers and payers. 
    • “The platform was developed alongside clinical and health plan leaders and is built to support HIPAA compliance, the tech giant said.
    • “The fundamental challenge in healthcare isn’t a lack of information—it’s the immense friction of making that data actionable across a highly regulated ecosystem,” said Thomas Kurian, Google Cloud CEO, in a statement. “By working directly alongside our healthcare customers, we’ve built a platform that resolves chronic bottlenecks so that the industry can put its focus entirely back on human health.”
  • Healthcare Dive offers
    • “7 healthcare experts on adopting AI tools
      • “When deciding whether to adopt AI tools, it’s crucial that healthcare organizations consider governance, clinician trust and overall costs, industry experts said at a Healthcare Dive virtual event.”
  • Per the American Hospital Association News,
    • “A Gallup survey published Nov. 9 on patient comfort with artificial intelligence in care found that 56% of U.S. adults who visited a primary care provider in the past year are comfortable with AI making diagnosis or treatment decisions, as long as they can be changed or overridden by their provider. The survey found that 38% of patients are comfortable when AI assists and their provider makes the decision. Results showed that 9% of patients are comfortable with AI making treatment decisions without provider review.”
  • Per Beckers Health IT,
    • “The American Medical Association has adopted policy saying AI cannot be granted physician licensure, professional titles or certification to practice medicine.
    • “The AMA House of Delegates approved the policy Nov. 9 at its Interim Meeting in Orlando, Fla. It calls for AI-enabled tools to be integrated into physician-led teams and used at the direction of the treating physician. AI used for for clinical functions such as diagnosis, prescribing and care management should have transparent, auditable evidence of safety and efficacy and be subject to regulation, documentation and liability requirements.
    • “The AMA will push for model legislation that separates authorization of a medical technology from professional licensure and bars misrepresenting nonhuman entities with titles reserved for physicians. It will also seek liability protections for physicians who decline to use an AI tool or follow its recommendation.
    • “Patients “deserve to know who is responsible for their care,” AMA President Willie Underwood III, MD, said in a Nov. 10 news release.”

Monday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC,

  • The U.S. Census Bureau informs us,
    • “Veterans Day originated as “Armistice Day” on Nov. 11, 1919, the first anniversary of the end of World War I. Congress passed a resolution in 1926 making it an annual observance, and it became a national holiday in 1938. Sixteen years later, then-President Dwight D. Eisenhower signed legislation changing the name to Veterans Day to honor all those who served their country during war or peacetime. On this day, the nation honors military veterans — living and dead — with parades and other observances across the country and a ceremony at the Tomb of the Unknown Soldier at Arlington National Cemetery in Virginia.
    • “The following facts are made possible by the invaluable responses to U.S. Census Bureau surveys. We appreciate the public’s cooperation as we continuously measure America’s people, places and economy. 
    • “Veteran Population
      • “15.7 million
        • “The number of military veterans in the United States in 2025, representing 5.9% of the total civilian population age 18 and over.
      • “0.3%
        • “The share of veterans in 2025 who served during World War II. Additionally, 2.3% of veterans served during the Korean War, 30.9% during the Vietnam War, 25.6% during the Persian Gulf War, and 31.4% during the Post-9/11 period (September 2001 to present).
      • “30.5%
        • “The share of veterans age 75 and older in 2025. At the other end of the spectrum, 8.4% of veterans were under age 35.”
  • The American Hospital Association News reports,
    • “The Centers for Medicare & Medicaid Services Nov. 9 announced allocations for the second year of the Rural Health Transformation Program, which will award $10 billion annually to all states from fiscal year 2026 through FY 2030. The program helps rural hospitals fund projects to expand access to care, bolster the rural workforce, modernize facilities and technology, and support innovative payment and care delivery models. Fifty percent of the funding is distributed equally among all states, while the additional 50% is allocated based on rural health needs and proposed impact.” 
  • Here is a CMS link to its fact sheet on this announcement.
  • Per a Department of Health and Human Services news release,
    • “The U.S. Department of Health and Human Services (HHS) today announced an expansion of the TOPx HHS Tech Sprint for AI and Invisible Illness prize pool from $2 million to $3.8 million, responding to strong public interest and the quality of submissions. Today’s announcement recognizes 40 Phase 2 winners receiving $3.7 Million from the expanded prize pool for working prototypes that use AI and federal open data to address complex chronic conditions.” * * *
    • Explore TOPx submissions and participate in People’s Choice voting at InvisibleIllness.Crowdicity.com. Learn more about HHS Lyme disease initiatives at HHS.gov/Lyme.
  • Beckers Hospital Review relates,
    • “CMS is seeking public comment on what should count as “reasonable and relevant” terms in contracts between Medicare Part D plan sponsors and network pharmacies, with comments due Nov. 23, according to a Sept. 24 request for information in the Federal Register. The SBA’s Office of Advocacy flagged the deadline to small businesses Nov. 9.
    • “Part D plans must already contract with any pharmacy that accepts their standard terms and conditions, and those terms must be “reasonable and relevant,” but CMS has never defined the phrase. The request is a first step toward implementing a provision of the Consolidated Appropriations Act of 2026 that makes the standards apply to plan years starting on or after Jan. 1, 2029.”

From the U.S. Office of Personnel Management front,

  • Fedweek reports,
    • “OPM has issued a memo seeking comment on how it plans to implement raises for federal law enforcement personnel in 2027 – while pay for most civilian personnel remains frozen.
    • “Covered law enforcement personnel will get a 3.8 percent raise, but newly covered groups could see a 2.77 percent catch up for last year on top of that, totaling around 6.7 percent. Those proposed groups include:
      • “GS employees in approved law enforcement officer (LEO) positions under 5 U.S.C. 5541(3), except those who qualify based on frequent direct contact with detained suspects or convicts
      • “GS-0083 Police, except VA police on title 38 special rates, whose adjustment will be handled separately
      • “GS-0080 Security Administration employees who regularly perform both physical security and law enforcement duties and have arrest authority
      • “GS-1811 Criminal Investigators
      • “Certain OIG positions. * * *
    • “OPM may separately set 3.8 percent special rates for CBP agricultural inspectors and certain firefighters, and it will contact agencies for staffing data, according to the memo. Coverage applies automatically unless agencies opt out by Nov 25. Special rates remain capped at $197,200, and the new special rates are expected by the end of the year.”
  • FedSmith discusses,
    • “The $7,500 Dependent Care FSA in 2027: Who Saves, and Who Should Take the Tax Credit Instead
      • “The Dependent Care FSA limit is now $7,500, but a rewritten tax credit means some federal families may come out ahead by skipping it this Open Season.”

From the U.S. Food and Drug Administration front,

  • Beckers Hospital Review reports,
    • “The FDA is requiring safety labeling changes for GLP-1 receptor agonists over a potential increased risk of a rare eye condition that can cause vision loss.
    • “The agency is requiring drugs including Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy to add information about non-arteritic anterior ischemic optic neuropathy, or NAION, to the warnings and precautions section of their labeling, according to a Nov. 9 drug safety communication. NAION can cause sudden, painless vision loss in one eye, which can be permanent. The FDA said it evaluated clinical trial, animal and postmarket data, including observational studies and case reports, in reaching its decision.”
  • The Wall Street Journal adds,
    • “Dozens of patients have sued Novo Nordisk and Eli Lilly, the biggest makers of these drugs, arguing the medications caused them to lose vision. The companies are fighting the lawsuits and have said previously that studies don’t prove any GLP-1s cause NAION. 
    • “A spokeswoman for Eli Lilly said the company is evaluating the FDA update and will respond to the agency soon. A Novo spokeswoman said the company continues to monitor the safety of its medicines and work with regulators, and that it remains confident the benefits outweigh the risks of its GLP-1s.” 
  • Fierce Healthcare relates,
    • “The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients, as concerns flare up over genomic insertion risks.
    • “Friday, the FDA confirmed it is evaluating cases of tumor formation in children previously treated with Zolgensma for spinal muscular atrophy (SMA). The agency’s diligence extends to Itvisma, a sister intrathecal formulation of the intravenously infused Zolgensma, as the two products contain the same vector and construct, even though Itvisma itself has no reported cases of tumor to date, the FDA said.
    • “At the center of the investigation is a biological process known as insertional oncogenesis, where the viral vector used to deliver functional copies of the therapeutic material inserts itself into human genes.” 
  • BioPharma Dive lets us know,
    • “The Food and Drug Administration on Monday approved a new kind of blood thinner meant to lower the risk of stroke in certain adults, marking a major milestone for cardiovascular research as well as the medicine’s developer, Bayer.
    • “The pill, which will be sold under the brand name Sunharbo, doesn’t work like established stroke prevention drugs. It inhibits a blood-clotting protein called Factor XIa. While this protein plays a minor role in sealing up blood vessels after an injury, it also amplifies a coagulation “cascade” that helps clots grow and makes them harder to break down, increasing the risk of strokes or heart attacks.”
  • MedTech Dive tells us,
    • “Novocure has been denied Food and Drug Administration approval for its device intended to treat non-small cell lung cancer that has spread to the brain.
    • “The FDA’s not approvable letter cited uncertainty around the degree of clinical benefit provided by Novocure’s device, Optune Mya, the company said Monday. The system uses low-energy electrical fields to disrupt cancer cells’ ability to grow and divide.
    • “The regulator did not raise concerns about the device’s safety profile, Novocure said. The company intends to meet with the FDA to determine if there are other options that would support approval without additional clinical studies.”
  • Fierce Pharma notes,
    • “Eli Lilly could soon see two label expansions for Foundayo, its oral GLP-1, in swift succession: In September, the drugmaker filed for U.S. review in Type 2 diabetes. And now, with new phase 3 data in hand, Lilly plans to approach the FDA about an application for obstructive sleep apnea (OSA).
    • “Backing the potential OSA label expansion is Lilly’s two-study, phase 3 Attain-OSA trial, presented Monday at the American Heart Association (AHA) Scientific Sessions 2026 and published in JAMA. At 52 weeks, the collective 712-patient program met its primary endpoint, with Foundayo (orforglipron) significantly reducing sleep apnea severity as measured using the standard apnea-hypopnea index (AHI) disease rating scale.” 
  • and
    • “Veradermics’ hair loss data package looks to be FDA-ready.
    • “Topline results are in for part B of the New Haven biotech’s phase 2/3 clinical trial in men with mild-to-moderate pattern hair loss, and the drug candidate, VDPHL01, did not disappoint. VDPHL01 achieved continued hair growth through one year and reported its highest hair count in the phase 3 program so far.
    • “VDPHL01 is an oral extended-release formulation of minoxidil—best known for being the active ingredient in Rogaine. Minoxidil was originally approved in the 1970s as a treatment for high blood pressure. Today, the generic is commonly prescribed off label as a hair-loss treatment, but the instant-release formulation can come with unwanted cardiac side effects and less-than-optimum impacts on hair growth. Veradermics attests that its extended-release design provides a steady absorption for better hair growth while avoiding the high concentrations that impact blood pressure.” 
  • The American Hospital Association News informs us,
    • “The Food and Drug Administration is seeking feedback on a discussion paper released Nov. 6 on the benefits and risks of robotic medical devices with autonomous or remote teleoperation capabilities. The paper discusses devices intended for surgical procedures and those with nonsurgical applications such as positioning or controlling instruments or imaging tools to perform specific tasks. Comments on the paper are due by Jan. 5, 2027. The discussion paper follows guidance the agency released in September that includes recommendations on nonclinical testing, clinical data and labeling for premarket submissions of certain robotically-assisted surgical devices. The FDA seeks comments on the draft guidance by Nov. 24.”

From the judicial front,

  • Fierce Healthcare reports,
    • “Elevance Health is the latest insurer to sue the feds over its performance in the latest round of star ratings for the Medicare Advantage program.
    • “The company sued the Centers for Medicare & Medicaid Services in District of Columbia federal court on Friday, arguing that the 2027 star ratings calculations violated the Administrative Procedure Act in using 11 measures that it says were adopted unlawfully.
    • “In the lawsuit, the company said that the harm from including these measures is “concrete and substantial.” If they were excluded, it would increase the scores for 12 of its Medicare Advantage contracts and generate $516 million in additional quality bonus payments.”

From the public health and medical / Rx research front,

  • Beckers Clinical Leadership points out “seven infection threats hospitals are tracking this winter.”
  • The New York Times adds,
    • “On the last Friday in August, Gay Rabb Small went for her daily walk along the Tampa shore. Nearing 80, she was determined to stay healthy and walked at least five miles a day.
    • “That night at dinner, her daughter, Anna Small, noticed that her mother seemed a little off. “I thought she had overdone it,” Ms. Small said.
    • “By Saturday, Gay Small had developed a tremor, and her daughter took her to the emergency room, where she was diagnosed with dengue, a viral illness transmitted by mosquitoes. She died the following Friday, Sept. 4, her 80th birthday.
    • “Gay Small got dengue from a mosquito bite, probably from one of her daily walks. She is so far the only fatality among hundreds of people in Florida who have been sickened in a dengue outbreak that scientists and public health officials are struggling to understand. The size of the outbreak, they say, indicates that dengue may be making a comeback in the continental United States at a level not seen for many decades.” * * *
    • Dr. Gabriela Paz-Bailey [from the CDC] said she did not expect to see “explosive” outbreaks like in Puerto Rico because of the higher standard of living in the continental United States. “But I do think that we will continue to see locally acquired dengue — that this will become the norm,” she said.
  • STAT News relates,
    • “High blood pressure has earned its reputation as the silent killer. If someone has diabetes or has had a stroke, the risk of serious cardiovascular events posed by hypertension climbs even higher.  
    • “Three studies presented Saturday at the American Heart Association’s scientific sessions reported on recent attempts to lower blood pressure in people with these challenging medical histories, and how medical care should reach across specialties to treat them. One small but diverse trial tested a common diuretic after a stroke, another looked at intensifying treatment to reach lower-than-standard post-stroke blood pressure goals, and the third looked at going lower in people living with type 2 diabetes. 
    • “Each of the scientists leading the studies and the experts commenting on them at a media briefing emphasized the role of blood pressure. Adding a widely available drug earlier held promise for controlling blood pressure, but it was a split decision between the effects of lower numbers post-stroke and with diabetes.”
  • Health Day adds,
    •  Valvular heart disease (VHD) death rates increased from 2018 to 2023 and are predicted to remain higher than prepandemic levels through 2040, according to a study presented at the American Heart Association Scientific Sessions 2026, held from Nov. 6 to 9 in Chicago.
    • Hritvik Jain, M.D., from Allegheny General Hospital in Pittsburgh, and colleagues examined trends in VHD among older adults. The analysis included age-adjusted mortality rates (AAMR) using data from the U.S. Centers for Disease Control and Prevention WONDER database (1999 to 2023) for adults aged 65 years and older.
  • and
    •  Patients with early-onset Alzheimer disease (EOAD) have more extensive deposits of tau compared with those with late-onset Alzheimer disease (LOAD), according to a study published online Nov. 4 in Science Translational Medicine.
    • Konstantinos Chiotis, M.D., Ph.D., from the Weill Institute for Neurosciences at the University of California, San Francisco, and colleagues compared baseline and longitudinal tau positron emission tomography (PET) burden measured with 18F-flortaucipir and its relationship with clinical variables in amyloid PET-positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (390 participants with EOAD) and Alzheimer’s Disease Neuroimaging Initiative (211 participants with LOAD).
  • Cardiovascular Business offers more insights from the American Health Association’s recent scientific sessions.
  • The American Medical Association lets us know what doctors want patients to know about urinary incontinence
    • “Urinary incontinence becomes more common with age, but patients do not have to live with it. Kegel exercises are one option that may help.”
  • BioPharm Dive informs us,
    • “An experimental two-drug combination from Vir Biotechnology has succeeded in the first of three Phase 3 trials against chronic hepatitis D, the company said Sunday. 
    • “Vir’s drugs, “elebsiran” and “tobevibart,” met their main objective in the study by largely eliminating detectable signs of the virus and normalizing levels of an important liver enzyme in 44% of treatment participants after 48 weeks. By comparison, none in a “delayed treatment” cohort achieved those results, according to Vir. 
    • “The regimen also met a key secondary endpoint focused solely on dropping viral levels, with 79% of treated patients achieving a treatment response. 
    • “Two additional Phase 3 trials are ongoing and should produce data early next year. Results from all three studies, if positive, would support a regulatory submission in 2027.” 

From the U.S. healthcare business and artificial intelligence front.

  • Healthcare Dive reports,
    • “More than 500 U.S. hospitals are owned by private equity firms, representing 11.9% of all private hospitals, according to new data from the watchdog group Private Equity Stakeholder Project.
    • “PE firms also own around a third of all for-profit hospitals in the U.S., according to the data.
    • “A small group of investors own the bulk of PE-owned facilities, the PESP data added. Apollo Global Management, which owns Lifepoint Health and ScionHealth, owns 200 facilities in the U.S. Meanwhile, the firm Welsh, Carson, Anderson & Stowe owns 124 facilities.”
  • Beckers Clinical Leadership points out,
    • “Hospitals with better nurse staffing levels had lower average emergency department boarding times than hospitals with high patient-to-nurse ratios, a recent study found.
    • “The study, published in the November issue of the Journal of Emergency Nursing, analyzed nurse staffing data and ED boarding times from 335 hospitals in Florida, New Jersey and Pennsylvania. 
    • “In hospitals with patient-to-nurse ratios of four or fewer, the average ED boarding time was about 20 minutes shorter than in hospitals where nurses cared for five or more patients. The study authors said improving nurse staffing levels is “often overlooked as a strategy” to cut boarding times and improve patient throughput.” 
  • Beckers Hospital Review relates,
    • “Palo Alto, Calif.-based Stanford Medicine and Sacramento, Calif.-based Sutter Health held a ribbon-cutting ceremony ahead of the planned Dec. 1 opening of the Stanford Medicine Sutter Health Cancer Center in Oakland, Calif.
    • “The outpatient cancer center is located on Sutter Health’s Alta Bates Summit Medical Center campus, according to a Nov. 9 news release from Stanford Medicine.
    • “The center will offer outpatient clinics, infusion, imaging, radiation oncology, ambulatory surgery, breast health and pharmacy services, along with clinical research, genetic counseling, nurse navigation and survivorship programs.”
  •  and
    • “Morgantown, W.Va.-based WVU Health acquired Wheeling, W.Va.-based Orchard Park Hospital Nov. 1, according to a news release.
    • “The hospital now operates as a remote campus of WVU Medicine Wheeling Hospital and has been renamed WVU Medicine Healthy Minds – Kids. The facility held a ribbon-cutting Nov. 9 and will continue Orchard Park’s specialized behavioral and mental health care for children.
    • “The acquisition continues WVU Health’s system expansion. In October, the system acquired Greensburg, Pa.-based Independence Health System’s five hospitals and their affiliated physician practices and outpatient facilities.”
  • BioPharma Dive tells us,
    • “Argenx, a Netherlands-based biotechnology company focused on antibody drugs, on Monday said it has agreed to acquire a protein specialist in a potentially billion-dollar-plus deal.
    • “Unnatural Products has a platform that pairs machine learning, screening and other techniques to engineer “macrocyclic peptides.” These peptides are larger and more complex than typical small molecules, which allows them to more effectively bind to tricky proteins and address some challenging diseases. Yet, they’re still tiny enough that they can be swallowed. Argenx plans to use the platform to develop oral, durable medicines for serious immune-mediated diseases.
    • “The acquisition carries a $550 million upfront cash payment. Unnatural Products could receive up to $595 million more if specific milestones are hit. The companies expect their deal to close before the end of the year.”
  • Fierce Healthcare informs us,
    • “HealthTap is rolling out a new program for Medicare Advantage plans that seeks to help members form a connection with a primary care doctor that carries forward.
    • “The program leans on a combination of proactive outreach and access to a patient’s historical medical records to support plans in identifying needs or risks, filling care gaps and coordinating follow-up or other necessary care. It’s built to directly support individuals who may not have a PCP on file.
    • “HealthTap reaches out to those members proactively, the company said, and helps them schedule an initial virtual visit with a provider who stays connected for preventive services, chronic condition management and medication concerns.”
  • Per Healthcare Dive,
    • “Hospitals collectively lost an estimated $132 billion last year due to write-offs for bad debt and final claim denials, according to a new report from revenue cycle analytics company Kodiak Solutions.
    • “Revenue leakage was up by nearly 18% compared to 2024, as hospitals continued to see write-offs take up about 10 percent of net revenue last year, the analysis of Kodiak’s proprietary data showed.
    • “This increase comes in the face of rising revenue cycle technology budgets, with more AI tools coming to market promising to improve hospitals’ financial performance, Kodiak executives said.”

Weekend Update

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC

  • Roll Call discusses what is likely to happen on Capitol Hill this week.
  • The Federal Benefits Open Season begins at noon (ET) tomorrow. OPM adds,
    • “The Federal Benefits Open Season ends at 11:59 pm Eastern Time on Monday December 14, 2026 for the Federal Employees Dental and Vision Insurance Program (FEDVIP) and the Federal Flexible Spending Account Program (FSAFEDS). Open Season for the Federal Employees Health Benefits Program (FEHB) and Postal Service Health Benefits Program (PSHB) ends at 11:59 pm, per the location of your electronic enrollment system, on Monday December 14, 2026.”
  • Beckers ASC Review reports,
    • “Physician leaders warn that CMS’ 2027 Medicare physician fee schedule final rule will put more strain on independent practices and make it harder for patients to get care.
    • “The final rule, released Nov. 4, cuts the conversion factor 2.31% to $32.63 for physicians who aren’t qualifying participants in an advanced alternative payment model. CMS had proposed a 1.68% cut in July. Much of the drop comes from the expiration of a temporary 2.5% payment increase for 2026. The rule also finalizes a 20% payment reduction for certain evaluation and management services billed with modifier 25 on the same day as a zero-day global procedure.”
  • Contemporary OB/GYN tells us,
    • “The Centers for Medicare & Medicaid Services (CMS) has included the American Medical Association’s (AMA) new obstetric billing codes in the final 2027 Medicare Physician Fee Schedule, according to a statement from Camille A. Clare, MD, MPH, CPE, FACOG, president, American College of Obstetricians and Gynecologists.1 
    • “ACOG is deeply grateful to CMS for including AMA’s new obstetric codes in the final 2027 Medicare Physician Fee Schedule, and we look forward to ushering in a new system that will contribute to improved maternal health outcomes,” Clare said in part. “This change follows years of ACOG advocacy and will address several challenges related to the current method of billing for prenatal care services.” 
  • The FEHBlog guessed last Sunday that CMS would announce the Medicare Part B and D premiums after the national election day on November 3. We are now three business days past election pay with no announcement. Perhaps the announcement will be made this week.

From the public health and medical / Rx research front,

  • The New York Times reports,
    • Nutrient deficiencies are rare in the United States, thanks in part to advances in food fortification in the 1900s. But many people, especially those in certain high-risk groups, are still not meeting daily recommendations for some nutrients, said Teresa Fung, a nutrition professor at Simmons University in Boston.
    • Nutrient inadequacies typically don’t cause the obvious symptoms that severe nutrient deficiencies do, Dr. Fung said. But they sometimes cause more vague symptoms that can affect quality of life and increase the risk of certain health conditions.
    • [The article identifies] “five, commonly under-consumed nutrients in the United States, according to experts — and the signs you may be falling short.”
  • and
    • “Cardiologists have been on edge for months, waiting for the details surrounding recent reports of the stunning failures of two new heart drugs.
    • The drugs — pelacarsen and ziltivekimab — were widely expected to usher in a new era in preventing heart disease. Companies, betting on the drugs’ promise, made huge investments in developing them.
    • So when doctors saw preliminary announcements that the drugs were not helping patients in large clinical trials, many felt blindsided, although still hopeful that there was more to the story than they knew.
    • “The whole cardiovascular community was gobsmacked,” said Dr. Karol Watson, a director of UCLA’s preventive cardiology program.”
    • Were the drugs close to succeeding, just barely missing a statistically significant benefit? Or were there at least subgroups of patients who were helped?
    • “Now the answers are in. There was not a shred of evidence that the drugs helped anyone. By every measure, they were no better than placebos.
    • “The results, Dr. Watson noted, “are about as neutral as they can be.” The full data were presented on Saturday morning at the annual meeting of the American Heart Association and in simultaneous publications in The New England Journal of Medicine.”
  • The Washington Post relates,
    • “The humble flu shot may have a hidden talent: fighting cancer.
    • “In a small clinical trial in Ohio, doctors injected an ordinary flu vaccine straight into patients’ skin tumors, hoping to fool the immune system into mistaking the cancer for an infection.
    • The ruse seemed to take. Immune cells flooded into most of the injected tumors. By the time surgeons cut the cancers out, more than a third of patients showed signs that their tumors were in retreat. In a few, no trace of cancer remained.
    • “The trial involved just 18 patients and lacked a comparison group, so the findings are far from proof that the approach works. But they hint at a possibly inexpensive, off-the-shelf way to help cancer patients and offer an alternative to cancer vaccines, a field that has lately centered on bespoke, highly expensive shots built to match the mutations in each patient’s tumor. The findings were presented last week at the Society for Immunotherapy of Cancer’s annual meeting in Phoenix.”
  • Cardiovascular Business tells us,
    • “The Society for Cardiovascular Angiography and Interventions (SCAI) released updated cardiogenic shock classifications to help clinicians better identify patients at risk, assess disease severity, and determine whether treatments are restoring adequate organ perfusion.
    • “The 2026 SCAI SHOCK Classification Expert Consensus Update, published in the Journal of the SCAI (JSCAI) in conjunction with the 2026 American Heart Association (AHA) Scientific Sessions, represents the third iteration of the classification system first introduced in 2019.[1] The framework has become widely adopted in clinical care, research and regulatory settings as a common language for communicating cardiogenic shock severity.
    • “Srihari Naidu, MD, FACC, FAHA, MSCAI, immediate-past SCAI president and director of the catheterization laboratories at Westchester Medical Center, was a co-chair of the consensus writing group. He said the update retains the familiar five-stage classification, A through E, while refining how clinicians identify patients at risk of deterioration and evaluate their response to treatment. Originally issued in 2019 and revised in 2022, this new iteration incorporates additional data from the past few years.
    • “We were happy that most of the data that had supported the shock classification and showed that really it was instrumental in improving shock care and really tracking with mortality. This is the third iteration of the shock classification, and I think people will agree that this has been a major step forward,” he said.
    • “One of the most important clarifications is the emphasis on tissue hypoperfusion rather than blood pressure alone when determining shock severity.”
  • Genetic Engineering and Biotechnology News informs us,
    • “Right now, there is no pharmaceutical treatment for obstructive sleep apnea, a condition that is estimated to affect more than one billion people globally and approximately 30 million Americans. Multiple studies (notably in 20101 and 20172) report that as many of half those prescribed continuous positive airway pressure (CPAP)—the gold standard apnea therapy—reject it outright, and between 12% and 25% of those who begin those treatments abandon CPAP within three years.
    • “The reason for such high non-compliance is that CPAP is uncomfortable and socially awkward, Joel Latham, president and CEO, Incannex Healthcare, says. His company aims to be the first to potentially market an oral pharmaceutical therapy for obstructive sleep apnea.
    • “Latham says Incannex Healthcare’s mission is “targeting indications that have limited or no treatment options available.” So, while a therapy for obstructive sleep apnea, known as IHL-42X, is its lead therapeutic, the company’s pipeline also includes therapeutics based on distinctly different therapeutic platform to treat generalized anxiety disorder and rheumatoid arthritis.”

From the U.S. healthcare business and artificial intelligence front,

  • Beckers Hospital Review reports,
    • “Hospital sales are picking up steam as various health systems under financial pressure look to trim underperforming assets, exit noncore markets and redirect capital toward strategic priorities. 
    • “Recent hospital divestitures have come from nonprofit giants carrying hundreds of millions of dollars in operating losses, for-profit operators completing full-state exits and other systems shedding community hospital portfolios they no longer consider core to their portfolios. 
    • [The article identifies] “10 large health systems that have sold or announced plans to sell hospitals this year.”
  • Healthcare Dive adds,
    • “It was a busy Thursday morning at the strip mall in White Hall, West Virginia. Once the sprawling grounds of Middletown Mall, the state’s first shopping mall before it shuttered in 2017, customers shuffled under a searing August sun between stores like Michaels, Five Below, Ace Hardware and Tractor Supply.
    • “You’d be forgiven for overlooking the catty-cornered building sandwiched between the Department of Motor Vehicles and across the two-lane road from the Italian pizzeria. 
    • “The bright red “Emergency” sign over the front entrance might get your attention though. Or the Marion County ambulances with their engines idling around back.
    • The building, containing just two hallways, is Mon Marion Neighborhood Hospital, part of a burgeoning trend of small acute care hospitals dubbed “micro-hospitals” or “neighborhood hospitals” that can hold anywhere from eight to 25 inpatient beds.
    • The micro-hospitals are popping up nationwide — from Pennsylvania to Arizona, Colorado to Texas — as lower-cost alternatives to traditional hospitals, including in semi-urban and rural areas where care access is strained.
    • “It’s been well received by the community,” said David Goldberg, the former CEO of Mon Health System, owner of Mon Marion. “Very busy, very widely accepted.”
    • “Micro-hospitals differ from freestanding emergency rooms or urgent care, two types of care sites that are offered as solutions to the rural care crisis because they have inpatient care capabilities. Though diminutive, the facilities are certified as hospitals according to federal standards set by the CMS.”
  • Fierce Healthcare relates,
    • “Omada Health saw its “strongest quarter ever” in the third quarter of 2026, CEO and co-founder Sean Duffy told investors and analysts during a Thursday evening earnings call.
    • “We delivered our highest quarterly revenue, gross margin progression, and our most profitable quarter to date,” Duffy said.
    • “The virtual chronic care provider, which went public last June, brought in $91 million in revenue—up 34% year-over-year—and reported gross margin of 76% on a GAAP basis and 78% on a non-GAAP basis, according to Duffy. Omada reported net income of $7 million in the third quarter, compared with a net loss of $3 million in Q3 2025.
    • “The company also reported adjusted EBITDA of $12 million, compared to $2 million the year prior. 
    • “It beat Wall Street analysts’ estimates for revenue, though slightly trailed behind projections for total membership.
    • “Total members reached 1.1 million, up 36% year-over-year, with trailing 12-month revenue per total member increasing 5% year-over-year to $294, according to financial results publishedThursday. Average member tenure also grew 10% compared to the year prior, to approximately two years and four months. Member retention has improved to 58%, up from 43% in Q4 of 2024, executives said.”
  • Beckers Payer Issues tells us,
    • “Aetna left the ACA market at the beginning of 2026, citing underperformance. Other insurers have also been navigating a rocky ACA landscape, marked by the expiration of enhanced premium subsidies and shifting risk-pool dynamics.
    • “CVS Health previously recorded a $448 million premium deficiency reserve in the first quarter of 2025 for its individual exchange business related to expected losses that year. During that quarter’s earnings call, former CFO Tom Cowhey had projected losses for the individual exchange business between $350 million and $400 million for full-year 2025.
    • “Aetna CFO Andreana Santangelo recently joined the Becker’s 5th Annual Fall Payer Issues Roundtable and shared more about the decision. 
    • “Very early on, you could see that we just didn’t have the right cost structure for our ACA business,” she said. 
    • “Citing her experience at a Blues plan and at Cigna, Ms. Santangelo said considerations around scale and cost structure are especially important for that business line. 
    • “While addressing how scale can be about more than sheer numbers, Ms. Santangelo said that “scale is also about having the right kind of risk pool” and attracting the right people who will find value in the product.”
  • Fierce Healthcare informs us,
    • “Equiti is acquiring Lexi AI to build a hybrid language-access model that combines AI language support with human medical interpreters. 
    • “Equiti, which sells medical interpretation services to hospitals and health systems through its Martti business, provides 24/7 access to qualified medical interpreters across more than 250 languages and dialects. Lexi provides multilingual, AI-powered medical interpretation. The acquisition deal merges Lexi’s immediate AI language support, covering over 35 languages and dialects, with Martti and its network of qualified medical interpreters to help healthcare organizations expand language access.
    • “The acquisition was announced October 28. Financial details of the deal were not disclosed.”

Thursday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC,

  • Beckers Hospital Review reports,
    • “CMS proposed a sweeping deregulation rule Nov. 5 that would remove hospital staff training requirements tied to Biden-era obstetric standards. It would also roll back several nursing home requirements, rescind a Medicaid payment transparency rule and exempt certain critical access hospitals from distance requirements.
    • “The proposed rule follows a CMS review of the conditions of participation for all 21 provider and supplier types. Providers must meet these baseline standards to bill Medicare and Medicaid.
    • “CMS said the rule is meant to eliminate obsolete or excessively burdensome requirements so healthcare organizations can devote more time and resources to improving patient care.
    • “The agency estimates the proposals would save $320 million a year and return more than 3.26 million hours of staff time to providers. Nursing homes would see the largest share at $142.6 million a year. Hospitals would save $123.2 million, CAHs $16.6 million and intermediate care facilities for individuals with intellectual disabilities $6.6 million. Rescinding a Medicaid payment reporting requirement accounts for another $30.4 million.”
  • and
    • “CMS has finalized a rule that sets ongoing policies for the Medicare Drug Price Negotiation Program, starting with negotiated prices that take effect in 2029.
    • “The agency said the rule is designed to give drugmakers in the program a clearer, more predictable process going forward, according to a Nov. 5 news release.
    • “CMS plans to pick up to 20 additional Part D or Part B drugs for the program’s fourth negotiation cycle by Feb. 1, 2027. It may also select previously negotiated drugs for renegotiation.
    • “This rule provides additional tools to help CMS negotiate better deals, achieve greater savings for taxpayers and beneficiaries, and improve health outcomes for seniors who rely on the Medicare Prescription Drug Program,” CMS Administrator Mehmet Oz, MD, said in the release.”
  • and
    • “HHS’ Administration for Strategic Preparedness and Response, the Commerce Department’s Bureau of Industry and Security and the Department of War’s health affairs office are assessing the U.S. industrial base for pharmaceutical key starting materials. The materials are the chemical precursors and intermediates used to make active pharmaceutical ingredients.
    • “The assessment will examine the upstream supply chain behind U.S. drug manufacturing, including limited domestic production capacity and reliance on foreign or single sources of critical materials, according to a Nov. 3 news release. BIS is surveying U.S. manufacturers, chemical suppliers, distributors, procurers and customers under Section 705 of the Defense Production Act. The one-time survey collects information on production capabilities, sourcing practices, customers, supply chain disruptions, workforce and research and development.
    • “The findings will be compiled into a report on U.S. production capacity, supply chain vulnerabilities and emergency response capabilities, with recommendations to improve resilience and public health emergency preparedness. The government plans to use the findings to develop funding strategies for the availability, quality and security of the materials.”
  • STAT News adds,
    • “Medicare will finalize a controversial proposal that will prevent providers, such as hospitals, from using third parties to deliver remote patient monitoring services, brushing away widespread opposition to the idea. However, Medicare will delay implementing the rule for two years to give providers enough time to hire and train staff to deliver the services. (I pulled the RPM section of the fee schedule here.)
    • “A common use case for RPM is using a connected blood pressure cuff to monitor a patient’s response to hypertension drugs and helping them manage the condition. Despite evidence RPM can be helpful for patients, use of the services has soared, and Medicare is worried about fraud in RPM billing.” 
  • Per a Health and Human Services Department news release,
    • “Women with higher blood levels of two common per- and polyfluoroalkyl substances, also familiarly known as PFAS, were more likely to develop estrogen receptor-negative, or ER-negative, breast cancer, according to a new study by the National Institutes of Health (NIH), part of the U.S. Department of Health and Human Services (HHS). PFAS are a large group of chemicals used in common consumer products. Often referred to as “forever chemicals,” PFAS do not break down easily in the environment and can remain in the body for years.
    • “The study found that women with higher blood plasma levels of two of these substances, perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS), were associated with a higher incidence of ER-negative breast cancer. No clear association was observed between the two chemicals and breast cancer risk overall.
    • “Women deserve clear answers about how chemicals in their environment may affect their health,” said HHS Secretary Robert F. Kennedy, Jr. “This NIH study links two forever chemicals to a higher risk of ER-negative breast cancer and demands further investigation. Under President Trump’s leadership, we will pursue the evidence, confront environmental health risks, and give women the information they need to protect their health.”

From the U.S. Office of Personnel Management front,

  • FedSmith advises,
    • “Protect Your FEHB Benefits: Who Qualifies, What to Verify and How to Keep Coverage.”
      • “Review your family’s FEHB eligibility before Open Season. Learn who qualifies, what documents may be required and how to avoid losing coverage for eligible family members.”
  • Tammy Flanagan, writing in Govexec, suggests,
    • “Make these health coverage decisions before you retire
      • “From FEHB eligibility rules to Medicare enrollment deadlines, the right steps before your last day can protect coverage for you and your spouse.”

From the U.S. Food and Drug Administration front,

  • Cardiovascular Business reports,
    • “The U.S. Food and Drug Administration (FDA) has confirmed that a safety issue with certain accessories used to implant the Sapien M3 transcatheter mitral valve replacement (TMVR) system has been ruled a Class I recall. 
    • “This is the agency’s most severe recall classification. It means using the devices in question could cause “serious adverse health consequences or death.”
    • “This Class I recall only covers four specific lots of these devices: 67718561, 67804014, 67887043 and 67887044. Delivery systems distributed as part of those four lots should not be used to treat any patients going forward. However, all other delivery systems sold with the Sapien M3 TMVR system can be used as normal. 
    • “The FDA first released information about this recall in October while the issue was still under investigation. As the agency explained at the time, four lots of the Commander M delivery systems sold with the Sapien M3 TMVR systems were being recalled due to an increased risk of the balloons bursting during inflation. Four serious injuries and one death were linked to the issue.” 
  • Per an FDA news release,
    • “The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy. HNSCC is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies.
    • “Rybrevant Faspro is not indicated as a treatment for patients with oropharyngeal squamous cell carcinoma that is associated with human papillomavirus (HPV). 
    • “Approval was based on trial results showing that more than double the percentage of patients responded to the drug compared to currently approved therapies. This is the first approval in 10 years of a drug for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy.” 
  • The Acting FDA Director writes about “Delivering Answers and Hope for Rare Disease Families.”

From the judicial front,

  • Per a Human Rights Campaign news release,
    • [On November 4,] the Human Rights Campaign Foundation and the law firm Correia & Puth filed an application for a preliminary injunction in their federal lawsuit to block the Office of Personnel Management’s (OPM) prohibition on health insurance coverage for transgender medical care under the Federal Employee Health Benefits (FEHB) and Postal Service Health Benefits (PSHB) plans. Implemented this year, OPM’s mandate has subjected federal employees and their families to even higher barriers to access potentially life-saving medical care, forcing many to leave their jobs, take on heavier financial burdens or go without care altogether. As Open Season for enrollment in these healthcare plans ends on December 14, a preliminary injunction is crucial to prevent imminent harm to federal employees who need continuing gender-affirming care.”
  • The Wall Street Journal reports,
    • “Elevance Health sued autism-therapy provider the Perfect Child, alleging that it paid the company $160 million due to misleading claims over the last five years.
    • “The lawsuit, filed in New York state court on Wednesday, cites a Wall Street Journal article that detailed the Perfect Child’s practices of charging insurers rates that could exceed $30,000 a day and attempting to collect directly from families when they balked at the bills, despite promises they would face little or no out-of-pocket costs.”
  • Beckers Hospital Review relates,
    • “A federal judge has lifted CMS’ freeze on new ACA marketplace broker registrations, clearing the way for approximately 19,000 licensed agents and brokers to assist consumers with 2027 coverage.
    • “The U.S. District Court for the District of Maryland ruled Nov. 5 in favor of the National Association of Benefits and Insurance Professionals, which challenged the moratorium in an Oct. 15 lawsuit. The ruling immediately lifts the registration restrictions, with training for newly eligible agents and brokers set to begin Nov. 6, according to the association.
    • “CMS implemented the moratorium Sept. 22, blocking agents and brokers who had not registered with the federally facilitated Marketplace for the 2026 plan year from completing registration for 2027. The freeze was originally set to remain in effect through Feb. 1, 2027.”

From the public health and medical / Rx research front,

  • Beckers Clinical Leadership reports,
    • “An infant in Wisconsin has died of measles, the state’s first measles death since 1990, the Wisconsin Department of Health Services said Nov. 5.
    • “The coroner listed measles as the immediate cause of death. The department is withholding further details to protect the family’s privacy.
    • “Any death of a child is a tragedy and even more so when it is related to a vaccine-preventable disease,” DHS Secretary Kirsten Johnson said in the news release.
    • “As of Nov. 3, Wisconsin had reported 431 measles cases in 2026, the state’s highest count in more than 35 years. Nine patients have been hospitalized with severe symptoms. The department said official counts likely understate the outbreak’s reach because not every sick person seeks care or gets tested.”
  • Health Day relates,
    • “More than 6 in 10 American drivers admit they’ve driven while dangerously sleepy.
    • “A new National Sleep Foundation report estimates 145 million adults have driven drowsy, including nearly 35 million who do so at least monthly.
    • “And about 40% don’t recognize warning signs like frequent blinking, head-nodding or drifting out of their lane.
    • “Drowsy driving is responsible for 1 in 5 deadly crashes, according to data cited in the report.
    • “Every signal in this year’s report points the same way: Drowsy driving is common, it’s under-recognized and the public is ready for solutions,” said Joseph Dzierzewski, senior vice president of research and scientific affairs at the foundation. “When 4 in 10 drivers can’t identify even the most basic of warning signs, too many people don’t realize they’re impaired and shouldn’t be behind the wheel.”
    • “The researchers say drowsy driving deserves the same serious attention as drunken driving.”
  • and
    • “Cutting-edge weight-loss drugs like Ozempic and Zepbound are helping people reverse prediabetes and avoid heart attack and stroke more effectively than standard diabetes medications, a new study says.
    • “People with prediabetes had 53% better odds of getting their blood sugar levels back to normal if they were taking a GLP-1 drug rather than the diabetes drug metformin, researchers are slated to report Monday at the annual meeting of the American Heart Association (AHA) in Chicago.
    • “They also were less likely to develop type 2 diabetes or suffer life-threatening heart problems on a GLP-1, researchers said.
    • “The great news with prediabetes is that it’s still possible to reverse the progression of the disease,” investigator Dr. Vinicius de Sousa Barzon Serra said in a news release. He is a research fellow in the department of cardiovascular medicine at the Mayo Clinic in Scottsdale, Arizona. 
    • “This research may add to the case for considering GLP-1 medications earlier for certain patients, rather than waiting until they develop Type 2 diabetes,” he said.”
  • Healio adds,
    • “Bariatric surgery can offer long-term cancer-protective effects for people with obesity regardless of their sex or age, findings of a population-based cohort study suggest.
    • “An analysis of registry data from nearly 800,000 people showed those who underwent the procedure exhibited an overall significantly lower risk for 10 obesity-related malignancies.
    • “The magnitude of risk reduction remained consistent between younger and older adults, and analyses that focused on cancer types that affect both sexes showed comparable benefits for men and women.”
  • MedPage Today tells us,
    • “The share of newborns who missed routine vitamin K shots rose to 6.8% in 2025.
    • “Infants who didn’t receive vitamin K shots faced a 47% higher bleeding risk in their first 6 months of life.
    • “Newborns without vitamin K shots also had doubled intracranial hemorrhage and bleeding-related death risks.”
  • STAT News informs us,
    • “When statins aren’t enough, other cholesterol-lowering drugs come into play. But which one is most effective?
    • “Cardiologists looking to help their patients reduce the amount of LDL, or “bad,” cholesterol threatening to clog their coronary arteries often consider two long-approved drugs, each acting through a different mechanism delivered by a different route. A new trial based on real-world evidence pitted the injectable PCSK9 inhibitor evolocumab, sold by Amgen as Repatha, against the oral cholesterol absorption inhibitor ezetimibe, now generic but previously sold by Merck as Zetia.
    • “Repatha was the winner.” 
  • and
    • “Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, a surprising development that has raised concerns among families, physicians, and patient advocacy groups.
    • “The cases, which for the moment are being seen as only a potential safety signal, were publicized on Thursday by an advocacy group and on a Facebook page after Novartis earlier this week disclosed the information to neurologists. One advocacy group, SMA Europe, issued a statement saying that regulatory authorities are now examining the cases.
    • “The drugmaker issued its own statement saying that since its treatment — called Zolgensma — was approved in 2019, it has received nine reports of tumors in previously treated patients. Of those, two cases to date showed evidence that the tumors may be linked to the treatment itself.” 
  • Beckers Hospital Review points out,
    • “Active U.S. drug shortages stood at 225 at the end of the third quarter, similar to the past three quarters, according to the American Society of Health-System Pharmacists. The 87 new shortages reported through September nearly equal the 89 reported for all of 2025, and chemotherapy shortages in particular have outlasted drugmakers’ resupply estimates. The FDA’s databasecontinues to reflect new discontinuations weekly.
    • [The article identifies] 11 recent shortage and discontinuation listings, according to the FDA database.”

From the U.S. healthcare business and artificial intelligence front,

  • The Wall Street Journal reports,
    • “Cigna Group CI lifted its outlook and reported higher sales in the recent quarter, driven by growth in both its healthcare and pharmacy-benefit businesses.
    • “The healthcare company on Thursday reported a third-quarter profit of $1.44 billion, or $5.47 a share, compared with $1.87 billion, or $6.98 a share, a year earlier.
    • “Stripping out certain one-time items, earnings were $7.98 a share. Analysts polled by FactSet expected adjusted earnings of $7.52 a share.
    • “Total revenues climbed 5.6% to $73.68 billion, ahead of Wall Street models for $72.64 billion. The company attributed the growth to gains across both its namesake healthcare business and Evernorth Health Services.”
  • and
    • “Inside CVS Health, a small group of top executives spent months engaged in a strategic review that developed into a secret plan: a decision to split up the $400 billion healthcare giant, hiving off its ubiquitous pharmacies. 
    • “It was an unlikely and radical step. The stores, with CVS’s signature red-letter logo, weren’t only how Americans thought of CVS but also the heart of its identity as a healthcare giant. Chief Executive David Joyner, a longtime veteran at the company, publicly rejected a split when he landed the top job in 2024. 
    • “This year, the C-suite’s annual planning exercise delivered a different verdict. The company should break off its drugstores from the Aetna health-insurance unit and Caremark pharmacy-benefit manager. The breakup, revealed Tuesday, will put Aetna and Caremark into one company, and the approximately 9,000 retail pharmacies into another.
    • “The logic: Its balance sheet was strong enough to support the two resulting companies, and the breakup would create more agile, focused firms. “It basically gives you confidence and strength about how each of the businesses are going to perform,” Joyner said in an interview. 
    • “The board supported the move. CVS wanted to get ahead of dynamics reshaping the healthcare market. Regulators appeared increasingly hostile to healthcare conglomerates.”
  • Beckers Payer Issues adds,
    • “Oscar Health reported $167.3 million in profit for third-quarter 2026, compared to a net loss of $137.5 million in the same period last year.
    • “The company reported its third-quarter earnings Nov. 5. Oscar brought in $5.1 billion in revenue, a 72% year-over-year increase. That includes a $250 million benefit from updated risk adjustment estimates.
    • “Earnings from operations reached $178 million, up from a $129.3 million loss in the third quarter of 2025.
    • ‘The company’s medical loss ratio fell from 88.5% in third-quarter 2025 to 84%.
    • “Oscar’s membership grew about 27% year over year, nearing 2.7 million effectuated members as of Sept. 30.”
  • Fierce Healthcare relates,
    • “Clover Health is continuing to see strong traction in its Medicare Advantage plan, with membership growing 49% year-over-year in the third quarter to approximately 157,000 members.
    • “Alongside continued membership growth, executives touted the company’s star ratings from the Centers for Medicare & Medicaid Services for payment year 2028.
    • “We are incredibly proud that our flagship PPO plan achieved five stars for payment year 2028, making it the largest five-star PPO contract in the country,” Andrew Toy, Clover Health CEO, said during Wednesday’s earnings call. “Additionally, our HMO plan achieved four and a half stars, meaning 100% of Clover members are enrolled in plans rated at least four and a half stars for payment year 2028.” 
    • “Toy said the ratings give Clover “continued flexibility to invest” in benefits and affordable care access for members, adding that the company’s HEDIS quality performance remains “industry leading.”
  • Beckers Hospital Review tells us,
    • “Indianapolis-based Indiana University Health reported an operating income of $110 million (4% margin) in the third quarter, up from $6.4 million (0.3% margin) in the third quarter of 2025, according to its most recent financial report. 
    • “IU Health’s operating expenses were $2.6 billion for the three months ended Sept. 30, 2026, up from $2.4 billion the previous year. Total revenue was $2.7 billion in the third quarter of 2026, up from $2.4 billion in the third quarter of 2025.
    • “The system’s long-term debt was $3.3 billion as of Sept. 30, 2026.”
  • Beckers ASC Review informs us,
    • “McAllen, Texas-based UT Health RGV Surgery Center has joined the ASC network of Phoenix-based Atlas Healthcare Partners, marking Atlas’ expansion into Texas, according to a Nov. 5 news release shared with Becker’s.
    • “The center is part of a new collaboration between Atlas and the University of Texas Rio Grande Valley. It has four ORs and one procedure room and offers orthopedics, gastroenterology, surgical oncology, general surgery, podiatry, gynecology and ENT.
    • “Atlas partners with nonprofit health systems, including Banner Health, Corewell Health, ChristianaCare and Prisma Health, to operate 47 ASCs across eight states. The company performs more than 110,000 procedures a year and generates about $400 million in annual revenue.”
  • and
    • “Palm Harbor, Fla.-based American Vascular Associates has formed a strategic partnership with New England Endovascular Center, a West Springfield, Mass.-based provider of minimally invasive vascular and endovascular care, the organizations announced Nov. 4 in a news release shared with Becker’s.
    • “AVA is a vascular management and growth organization. It supports office-based labs and ASCs with operations, revenue cycle management, finance, IT, compliance, marketing, physician recruitment and growth strategy.
    • “NEEC was the first interventional and endovascular medical center in Western New England. It serves patients across the Pioneer Valley, the Greater Springfield region, the Berkshires and Northern Connecticut.”
  • STAT News points out,
    • “The commercial debut of Revolution Medicines’ pancreatic cancer drug Rasonquewas eye-popping and jaw-dropping: $198 million in sales in just five weeks following the U.S. approval of the groundbreaking pan-RAS inhibitor. More than 5,000 patients have already been treated with the drug, the company said Wednesday evening. 
    • “The U.S. launch of Rasonque is off to a strong start,” said Revolution Chief Commercial Officer Anthony Mancini, on the company’s earnings call — perhaps the understatement of the year in commercial biotech.”
  • Per Healthcare Dive,
    • “Mayo Clinic’s health tech innovation arm, Mayo Clinic Platform, has launched an artificial intelligence tool to bring patients’ medical information and relevant clinical evidence together during patient interactions, the health system said Tuesday.
    • “The solution offers clinicians specific guidance for more than 35 specialties, helping answer clinical questions, explore diagnoses and assess care options. The tool aims to reduce the time clinicians spend finding the information they need across different resources and to focus more on patient care. 
    • “The tool is available to clinicians at the Mayo Clinic and others who work for organizations that participate in Mayo Clinic Platform’s provider programs.”
  • Per MedTech Dive,
    • “Study results supporting Edwards Lifesciences’ transcatheter aortic valve replacement in patients with less severe disease were a highlight of the Transcatheter Cardiovascular Therapeutics conference.
    • “Also notable were findings on Medtronic’s renal denervation system in a broader patient population and the performance of Abbott’s Amulet 360 left atrial appendage closure device one year after implant.
    • “The TCT conference, which wrapped up in San Diego this week, is the Cardiovascular Research Foundation’s annual scientific symposium.”
  • and
    • “Edwards Lifesciences’ third-quarter sales exceeded its expectations, prompting the heart valve maker to raise its full-year forecast for the third time this year.
    • “Executives on Wednesday’s earnings call pointed to several catalysts for the business going forward, including data supporting expanded use of transcatheter aortic valve replacement to treat aortic stenosis.
    • “In the PROGRESS trial, presented this week at the Transcatheter Cardiovascular Therapeutics conference, Edwards’ Sapien 3 TAVR device demonstrated superiority to standard-of-care clinical surveillance in people with moderate aortic stenosis and at-risk features.”

Midweek report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From the national election front,

  • The Wall Street Journal reports.
    • “Vice President JD Vance blamed the Iran war for Republicans’ heavy midterm losses, saying “everyone knows why we lost.” The comments came a day after Democrats took control of the Senate and House in a blue wave that surged across the country, extending into traditionally red states in a repudiation of President Trump.
      • House: As more races are called, Democrats are expanding the majority they clinched in the chamber last night. [As of this writing, the Democrats have 237 seats and the Republicans 147.] Meanwhile, with House Speaker Mike Johnson saying he wouldn’t run for minority leader, House Republicans are already jockeying for the job.
      • Senate: Democrats have flipped seven seats so far in the Senate. [As of this writing the Democrats have 54 seats and the Republicans 44.] Two races have yet to be called in which the Democratic candidate currently has a slight edge over the Republican incumbent: Alaska and Mississippi. It’s unclear when those results will be announced.
      • Trump: The president appeared at the site where his ballroom is being constructed and took a few questions from reporters. Among other things he said Vance’s assessment of the impact that the war with Iran had on the midterms was “largely true” and that he wasn’t considering replacingDefense Secretary Pete Hegseth.
  • Beckers Hospital Review tells us,
    • “Health insurer and hospital stocks climbed Nov. 4 after Democrats won majorities in both chambers of Congress in the Nov. 3 midterm elections, as analysts said the new Congress could delay Medicaid cuts and restore enhanced ACA subsidies.”
  • Fierce Healthcare lets us know in more depth “what Democratic control of Congress means for healthcare in 2027.”
  • Beckers ASC Review points out “Physicians who won in the 2026 midterms.”

From the U.S. Office of Personnel Management front,

  • Govexec reports,
    • “Following the drubbing of congressional Republicans in Tuesday’s midterm election, federal employee unions are hopeful that the change in control on Capitol Hill will precipitate action to roll back some of the Trump administration’s efforts to reshape the federal workforce.”
  • Fedweek tells us,
    • “The annual federal benefits open season starting next Monday (November 9) and running through December 14 provides an opportunity for current enrollees change FEHB/PSHB health insurance plans’ change levels of coverage, for plans that have more than one; and change among self-only, family and self plus one options.” * * *
    • “Even enrollees happy with their same coverage should look at the offerings, experts advise, since benefits do change somewhat year to year. And within the average premium increase there is variation, with some plan premiums increasing by well more than the average.
    • “A summary of general changes to coverage terms in both programs is here; check a plan’s brochure for its specifics. OPM’s main open season resources page is here.
    • “Tables of plans leaving the programs or reducing service areas are here for FEHB and here for PSHB. Affected enrollees in these plans who don’t choose a new one will be moved to Compass Rose Standard if in FEHB and in FEP Blue Focus if in PSHB.”
  • and
    • “While most of the attention focuses on the FEHB health insurance program during the annual benefits open season—this year November 9-December 14—the open season also provides federal employees and retirees the opportunity to elect or change vision and/or dental coverage in the FEDVIP program, and for employees to begin or renew flexible spending accounts for the new year.” * * *
    • “Those who wish to have a dependent care and/or health care flexible spending account must make a new election during the open season. The IRS has not yet announced the maximums in those programs for 2027; for 2026, they were $7,500 individually or for a couple filing federal income taxes jointly ($3,750 for married individuals filing separately) for dependent care accounts and $3,400 (individually) for health care accounts.” * * *
    • “The open season does not apply to the other two federal insurance programs, the FEGLI life insurance program and the FLTCIP long-term care insurance program. FEGLI conducts open seasons only rarely, although new enrollments or coverage changes are allowed in certain circumstances at other times. The FLTCIP has not accepted new applications for enrollment or changes in existing enrollment since 2022; there has been no indication of that suspension being lifted.”
  • FedSmith discusses “Preparing for Medicare: FEHB Decisions at Age 65
    • “Learn how Medicare and FEHB work together at 65. Understand Medicare Part A, Part B, and make smart retirement healthcare decisions early.”

From the Medicare front,

  • Beckers Hospital Review notes,
    • “On Jan. 1, 2027, Medicare’s negotiated prices for 15 more drugs take effect, including the semaglutide products Ozempic, Wegovy and Rybelsus. They join the 10 drugs whose first-round negotiated pricestook effect this year. For hospital pharmacies, the date matters twice: several of the same drugs also move to rebate-only 340B pricing that day if the program takes effect as scheduled.”

From the U.S. Food and Drug Administration front,

  • STAT News reports,
    • “Democrats’ landslide victory in the midterm elections may have significant implications for the upcoming negotiations over a key funding source for the Food and Drug Administration, in part by empowering a major critic of the program.
    • “The FDA collects user fees from pharmaceutical companies to fund the agency’s reviews of their medicines. The Prescription User Fee Drug Act must be renewed before the current law expires on Sept. 30. Otherwise, it could disrupt the FDA’s ability to approve medicines.
    • “The power to shape that legislation will fall to senior Democrats, including Sen. Bernie Sanders (I-Vt.), who will likely lead the Senate’s health committee. Sanders is one of the few lawmakers who have opposed the core premise of the user fee structure.
    • “Now, he will have a chance to fundamentally alter how the FDA interacts with the companies it regulates.” 
  • Cardiovascular Business relates,
  • Contemporary OB/GYN shares professional “reactions to FDA’s boxed warning removals for menopausal hormone therapy.”

No Surprises Act News

  • The New York Times reports,
    • “The federal government plans to end contracts with two arbitration firms that settle medical billing disputes under the No Surprises Act, a consumer protection law that has come under scrutiny for high payouts for doctors.” * * *
    • “The arbitrators’ contracts last five years, and the government is now reviewing those awarded in 2022.
    • “Two firms, Island Peer Review Organization and Network Medical Review Company, were notified on Wednesday that the government does not plan to renew their contracts, according to a notice published that day.”

From the public health and medical / Rx research front,

  • Beckers Clinical Leadership reports,
    • “Lung cancer remains the leading cause of cancer death in the U.S. and sits at the intersection of several pressures health systems are already managing: an aging patient population, uneven access to screening and a disease that is still most often caught too late. 
    • “How lung cancer affects a health system depends heavily on where it operates. Incidence, mortality, screening and smoking rates, along with Medicare spending, vary widely from state to state.
    • “For healthcare leaders, those state-level differences can inform decisions about screening programs, patient volume and investment in early detection.
    • “Becker’s compiled a list of the facts and figures healthcare leaders need to know about lung cancer using data from the American Cancer Society, the CDC, CMS and a lung cancer screening study published Dec. 9, 2025, in CHEST.”
  • and
    • “Hawaii and Louisiana continue to report the highest percent of influenza-like illnesses as the U.S. experiences an earlier-than-usual flu season.
    • “The CDC defines influenza-like illness, or ILI, as a fever of 100 degrees or greater, along with a cough and/or sore throat. The agency collects data on outpatient visits to healthcare providers for respiratory illness through ILINet. ILI percentages are weighted for state population and compared to baseline levels to assess flu activity. For more information on how the metric is calculated, click here.
    • “Hospitals reported 6,100 new flu admissions in the week ending Oct. 24, up from 4,811 the week prior, according to the CDC’s latest FluView report. This accounts for a 27% week-over-week increasein flu admissions. 
    • “About 2.4% of outpatient visits involved patients with respiratory illness. This metric sits below the national baseline of 2.9% and is up from 2.2% the week prior.”
  • The Washington Post relates,
    • “Peanuts, and peanut butter in particular, are some of the most ubiquitous elements of a child’s diet, and so when a kid is allergic to them, it can be a unique vexation for parents. It means no PB&Js for lunch — but also an endless list of logistics, from having to check in with the parents any time their kid goes over to a friend’s house to communicating with school officials.
    • “It turns out that for many kids thought to have peanut allergies, much of that vigilance may not be necessary. 
    • “A new peer-reviewed study, published Nov. 4 in the Journal of Allergy and Clinical Immunology: In Practice, suggests that fewer young children than previously thought have long-lasting peanut allergies. The findings could change how we make early-childhood allergy diagnoses and how to think about treating allergies moving forward.”
    • “Tim Brettig, a pediatric allergist and immunologist, and a senior research clinician at the Murdoch Children’s Research Institute in Melbourne, Australia. said that means many parents who think their children have lifelong allergies to peanut butter might want to reexamine the matter carefully. “If you’ve had a clear reaction, I would be less inclined to accept a peanut allergy diagnosis,” said Brettig, one of the lead researchers on the new study. “I’d want to continue that work-up. I think food challenges should play a greater role in the allergy assessment of children. Give them a chance to prove that they’re not allergic.” 
    • “The key is a controlled environment, such as a doctor’s office, for checking again, Brettig said. About 12 percent of the babies given the oral food challenge did experience anaphylaxis, the whole-body and sometimes life-threatening reaction that is the most severe response to an allergen. But because they were in an environment with medical professionals to administer care, no long-term harm came to any of the children. “It’s not necessarily something that I’d be doing in a community setting,” said Brettig. “You’d want it to be done with specialists that are skilled in performing these food challenges.”
  • The New York Times adds,
    • “Kratom, long used by people seeking relief from addiction to prescription opioids and alcohol, is increasingly being pitched as a wellness product that purports to raise energy, sharpen focus and enhance athletic performance.
    • “Some makers of kratom, a substance that is derived from the leaves of a tropical tree and often sold in the form of drinks, powder or capsules, have distributed free samples at gyms. Others have sponsored sporting events or trumpeted the product’s benefits with the help of social media influencers and wellness podcasts.
    • “What this marketing often fails to acknowledge is the potential for kratom to lead to addiction, liver injury, seizures and in some cases, fatal overdoses.”
  • Healio tells us,
    • “Individuals with inflammatory bowel disease who have at least two first-degree relatives with colorectal cancer appear to have the greatest increase in risk for CRC, according to results of a Swedish cohort study.
    • “Analysis also showed that having a relative with early-onset CRC was associated with a more modest risk, a finding that diverges from prior research.”
  • Health Day informs us,
    • “Gestational weight gain (GWG) outside of recommended ranges is associated with increased severe maternal morbidity (SMM) risk, according to a study published online Oct. 22 in JAMA Network Open.
    • “Sahar Khademioore, from McMaster University Medical Center in Hamilton, Ontario, Canada, and colleagues examined the association between GWG and SMM across prepregnancy body mass index (BMI) categories.”
  • Per an NIH news release,
    • “Results from a clinical trial funded by the National Institutes of Health (NIH) in five major United States cities show that delivering integrated HIV and substance use disorder (SUD) services using peer navigation in mobile medical units reduced all-cause deaths by 71% compared to participants who received peer navigation to community-based services alone. While scientists found no difference in the use of daily, oral preexposure prophylaxis (PrEP) and medication for opioid use disorder (MOUD) between the groups, the secondary outcome of reduced mortality was significant. 
    • “Injection drug use is an important contributor to HIV in the U. S. that also increases risk for other serious infectious diseases,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA), which funded the study. “Although we have effective interventions for this population, there are significant barriers to their accessibility and use. Nonetheless, these findings suggest that delivering low threshold services through mobile units could save lives.” 
  • Beckers Behavioral Health adds,
    • “Researchers at St. Louis-based Washington University School of Medicine found that among patients presenting to the emergency department with a substance-related problem, cannabis was most common among adolescents while alcohol was most common among older adults. 
    • “The study, published Nov. 4 in The American Journal of Psychiatry, analyzed data from large health insurance databases for more than 1.3 million patients ages 16 to 64 who had at least one substance-related emergency care visit between January 2016 and December 2023. Researchers analyzed the data by age group and substance used.” 
  • BioPharma Dive points out,
    • “Sanofi has stopped development of an experimental protein-degrading immune disease drug licensed from biotechnology company Nurix.
    • “Nurix on Tuesday revealed Sanofi’s decision to scrap “SAR448272,” an oral medicine designed to eliminate STAT6, a protein involved in many inflammatory conditions. Nurix didn’t specify the reason for the decision, but Sanofi separately told analyst firm Leerink Partners “emerging nonclinical findings … didn’t warrant further development” in eczema, according to a note to investors. 
    • “Nurix received a $10 million payment from Sanofi in August when a Phase 1 study began and would’ve been eligible for additional payouts if the treatment moved forward in testing.”
  • and

From the U.S. healthcare business and artificial intelligence front,

  • The Wall Street Journal reports,
    • “CVS Health raised its full-year guidance on gains in its health-care benefits and pharmacy segments, but said it remains cautious amid high costs and potential macroeconomic headwinds.
    • “The outlook comes after the company said Tuesday that it plans to split in two, with one company housing its insurance giant Aetna and pharmacy-benefit manager Caremark, and the other its 9,000 retail pharmacies.
    • “CVS said the breakup, slated for early 2028, will enable the two separate management teams to focus more on their respective businesses and be more agile, The Wall Street Journal reported.
    • “For the current fiscal year, the company on Wednesday said it now expects adjusted earnings of at least $8.20 a share, up from its previous forecast of between $7.90 and $8.10 a share. Analysts polled by FactSet anticipate adjusted earnings of $8.05 a share.
    • “CVS also said it now projects revenue of at least $420 billion for the year, compared with its previous forecast of at least $414 billion. Wall Street is modeling for revenue of $417.7 billion.
    • “Each of our businesses delivered another quarter of strong results,” Chief Executive David Joyner said. “We continue to advance our strategy by improving the consumer experience, lowering health care costs, and connecting care for the people we serve.”
  • and
    • “Novo Nordisk raised its annual guidance due to an improved outlook for its key obesity and diabetes drugs.
    • “The Danish drugmaker now expects adjusted sales and operating profit to range from a 2% decline to 2% growth at constant exchange rates.
    • “Third-quarter sales of the Wegovy pill reached the equivalent of $807.2 million, beating analyst expectations of 4.5 billion kroner.”
  • and
    • “AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals RYTM 28.04%increase; up pointing triangle, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments. 
    • “The U.K. pharmaceutical giant offered to pay $124 a share for the biotech last month, the people said. 
    • “Rhythm specializes in treatments for metabolic conditions and severe obesity. Its shares were trading Wednesday afternoon at around $95 apiece before The Wall Street Journal reported on the offer. They closed up 28% at over $110 a share following the report, giving the company a market value of roughly $7.6 billion. AstraZeneca had a market value of close to $300 billion.”
  • Beckers Hospital Review lets us know how “Health system CEOs close margin gaps with operational redesign.”
  • Fierce Healthcare informs us,
    • “As health plans and employers contend with a growing array of virtual care and AI-enabled tools, Amwell is positioning its digital health platform as the infrastructure layer for AI-enabled care.
    • “Executives at Amwell, formerly known as American Well, touted the company’s platform strategy, government contracts and higher-value clinical services as the main drivers of future growth during the company’s third-quarter earnings call Tuesday.
    • “Rising healthcare costs are pushing health plans and employers to adopt tech-enabled care solutions, but they are looking for measurable engagement and outcomes from digital health vendors, not just access, according to Ido Schoenberg, M.D., Amwell chairman and CEO.
    • “The proliferation of point solutions, accelerated by AI, is creating more vendor sprawl and member confusion, Schoenberg told investors and analysts during the call.” * * *
    • “This is the problem Amwell is determined to solve for our customers. We help them improve clinical and financial outcomes. We do it through activation, getting more of their members into technology-enabled care in place of conventional care that often costs more. We give our customers one platform under their brand with one integration. It provides reliable, scalable rails to bring in a program, exchange data with it, and tests whether it works. The member’s experience stays consistent, simple, and engaging. A common data structure proves the outcomes and improves performance over time,” he said.
    • “As AI adoption grows, a unified care platform becomes more valuable, Schoenberg asserted.”